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SUMMARY
4 - [ llfC]Ethynylbiphenyl has been synthesised and its  metabolism 
studied in the ra t and the rabbit. 4 1-Hydroxy-4-biphenylylacetic  
acid and 4-phenylmandelic acid were synthesised for use as standards 
to aid id en tifica tion  of metabolites.
When 4 - [^C ] ethynyl biphenyl was dosed ora lly  to rats and rabbits 
(40 mg/kg) no unchanged parent drug was excreted in the urine or 
faeces. The excretion of radioactivity was more rapid in the rabbit 
than the ra t (72% a fte r 24h compared to 52%). The excretion time in 
the ra t was longer than in the rabbit.
The prolonged excretion observed in the ra t together with s ign ifican t 
amounts o f radioactivity appearing in the faeces suggested.that b ilia ry  
excretion and enterohepatic circulation occurs in this species. This 
has been confirmed in rats fit te d  with bile-duct cannulae. Entero­
hepatic circulation was greatly diminished by pretreatment with 1 ,4 - 
saccharo-lactone or with antib io tics.
The major metabolite excreted by the ra t and the rabb it was.4 '-  
hydroxy-4-biphenylylacetic acid. 4-Biphenylylacetic acid was found 
to be the secondary metabolite in both species (0-2% in  the r a t ,  2-4% 
in the ra b b it). 4-Phenylmandelic acid and 4-acetyl biphenyl -were . 
found as trace metabolites. The identities  o f these metabolites were 
confirmed by mass-spectroscopy and n.m.r.
The major metabolite, 4'-hydroxy-4-biphenylylacetic acid has been 
shown to be inactive as an inh ib itor of prostaglandin synthetase 
( in  v i t r o )  whereas 4-biphenylylacetic acid exhibited moderate a c tiv ity .
■ ~ i i  “ :
Metabolism of 4-ethynylbiphenyl was studied in- ra t l iv e r  sub- 
ce llu la r fractions, both normal and induced with phenobarbitone or
3-methylcholanthrene. The major metabolite observed was 4-biphenylyl- 
acetic acid and the metabolism of 4-ethynylbiphenyl, or more 
specifica lly  the acetylene group, was greatly induced by both pheno­
barbi tone and 3-methylcholanthrene. A mechanism is proposed to 
account for this novel metabolic transformation.
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Abbreviations and Conventions
In general the abbreviations used comply with those suggested 
by the Biochemical Journal.
This thesis is divided into five  chapters. The appendix and 
bibliography follow Chapter 5. Tables and figures are numbered 1 .1 .,  
1 .2 ., e tc ., the f i r s t  number referring to the chapter and the second 
to the order within the chapter.
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1.1 4-ETHYNYLBIPHENYL '■
Important classes of non-steroidal anti-inflammatory agents 
in current c lin ica l use are the aryl acetic and 2-aryl propionic 
acids. The success of these compounds has led to the search fo r  
new anti-inflammatory drugs with improved therapeutic indices that 
are structurally  sim ilar to the aromatic acids but which are not 
acids themselveSo This was the rationale behind the production of 
4-ethynylbiphenyl..
C= CH
4-Ethynylbiphenyl
This drug candidate is unusual in that i t  is purely hydrocarbon in 
structure. Few such compounds are considered for drug use. In 
addition, there is a terminal acetylene group d ire c tly  attached to 
an aromatic ring, and although acetylene groups are encountered in 
other drugs, they are frequently found as part o f a carbon side-chain 
in which the acetylenic bond is not term inal. The acetylene group 
and its  occurrence, chemistry, pharmacological significance, and 
metabolism is discussed la te r .
In order to investigate fu lly  the metabolic characteristics 
of 4-ethynylbiphenyl a wide range of toxicity and metabolic studies 
were carried out in a variety of animal species (Allen & Hanbury 
Ltd., Ware, Hertfordshire, unpublished findings). These studies 
revealed that the drug possessed good anti-inflammatory activ ity  
and was an inhibitor of the developing and established rat adjuvant 
arth ritis  tests, where its  potency compared well with known an ti-
inflammatory phenyl acetic acids and th e ir derivatives.
Further development of the drug was, however, halted when 
4-ethynylbiphenyl was found to be a very marked ir r i ta n t  o f the 
gastro-intestinal tra c t. When given ora lly  to rats a t a da ily  dose 
of 100 mg/kg for six weeks ulcers were formed. In the dog the 
toxici ty. was more pronounced and gastri c bleedi ng v/as apparent two 
to three days a fte r daily oral doses of 25 mg/kg. Rabbits, however, 
tolerated a daily oral dose o f 100 mg/kg for up to a month with no 
effec t upon the gastro-intestinal tra c t. S im ilarly , a marmoset was 
given up to 150 mg/kg twice daily fo r four weeks with no evidence 
of toxic e ffec ts .
The above studies were carried out using unlabelled 4-ethynyl 
biphenyl which made the isolation and id en tifica tion  of the drug and 
its  metabolites d i f f ic u lt .  Despite the unfavourable side-effects o f 
the drug in animal t r ia ls  i t  was decided to make a detailed study of 
the metabolism and actions of the.compound in view o f its  in teresting  
chemical structure and particularly  as the acetylene group was 
apparently undergoing metabolism, an unusual occurrence in other 
acetylenic drugs. In addition there was the possib ility  that a 
metabolite of the parent drug might prove useful as an a n ti­
inflammatory agent in its  own r ig h t.
CHEMISTRY OF ACETYLENES
The carbon-carbon double bond occurs frequently in drug and other 
molecules and its  metabolism has been widely investigated. The carbon- 
carbon tr ip le  bond on the other hand is rare and its  metabolism has 
been subjected to very l i t t l e  investigation. The two types of bond 
are quite d iffe ren t in many respects and i t  is worthwhile to consider
the physical and chemical differences between the two before looking 
a t the metabolism of acetylenes.
The acetylene molecule consists of two Sp-hybridized carbon atoms 
and two hydrogen atoms (only one hydrogen in mono-substituted acetylenes 
lik e  4-ethynylbiphenyl).. . One-.Sp-hybrid orb ital from each carbon over­
laps the S-orbital o f its  hydrogen atom, forming a sigma (6) bond.
The other sp orbitals overlapeach other endwise and the unhybridized 
p-orbitals form pi-bonds ( tt) by latera l overlap, thus forming the linear  
carbon-carbon tr ip ie  bond.
In the acetylene bond, unlike the ethylenic bond, the density 
distribution of the t t  electrons can be represented as a cylindrical 
cloud of electrons. In the ethyl enic bond, on the other hand, the t t  
electrons are not delocalized and the tt electron density d istribution  
can be pictured as two rods, one above and one below the carbon atoms. 
These differences are illu s tra ted  in Figure 1.1.
The physical structure of the two bonds can be used to explain 
important chemical differences observed between acetylenic carbon atoms 
and ethylenic carbons. The former are more susceptible to nucleophilic 
attack and less susceptible to e lectrophilic  attack than ethylenic 
carbons. This is because the C-H bond in the acetylene group is 
formed from an sp molecular o rb ita l, whereas that in the o le fin ic  
bond is formed from an sp2 type. The greater degree of s-character 
in the acetylene confers a lower energy state to the electrons in the 
bond. The consequence of this is the re la tive  s ta b il ity  o f the RC=C:~ 
ion compared to the R2C=CH:~ion. Thus acetylenes with the structure 
RC=CH have demonstrable, though very weak, ac id ity . Alkenes and 
alkanes have no acidic hydrogens.
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Figure 1.1.  Differences in electron distribution about the 
acetylene tr ip le  bond and the ethylenic double 
bond '
H
Acetylene 
a) side view b) end view
Ethylene
Because o f the a b ility  to form the acetylide anion acetylenes form 
s ilve r and cuprous sa lts , e.gc
RCeCH + Ag (NH3 ) 2 +  OH"  RC=C: Ag +  2NH3 + H20
Since most of the s ilv e r  and cuprous acetyl ides are insoluble compounds 
such reactions can serve as useful diagnostic tests fo r the presence 
o f the ethynyl grouping.
The acetylenic bond can be hydrated by the addition o f a water 
molecule in a reaction analogous to the hydration of alkenes to form 
alcohols, the-difference being that the intermediate alcohol is unstable 
and immediately rearranges to y ie ld  an aldehyde. Sulphuric acid and 
mercuric sulphate act as catalysts for the reaction0
HC=CH + H20 M y —► J HC = CH^ V —  ■> H -C-CH;
'' I  CH J 0
acetylene very unstable acetaldehyde
vinyl alcohol
The vinyl alcohol intermediate has never been isolated. All attempts 
have resulted in the formation o f the corresponding aldehyde.
Substituted acetylenes react in an analogous way (Rutledge, 1969), 
addition taking piace-according to Markovnikovls ru le , in which the 
more substituted carbon adds on the hydroxyl group and the intermediary 
vinyl alcohol rearranges to give a ketone:
RC=CH ------- ^  {  RC = CH2 I   R-C-CH3
OH J 0
In addition to metal complexes in which the acetylenic hydrogen 
is substituted, complexes with metals are found in which the t r ip le  
bond is unchanged. Very few examples of such complexes are described
however, because th e ir  cata ly tic  significance in preparative chemistry 
is small. From a biochemical viewpoint however, the significance may 
be much greater i f  such complexes could be formed with metal atoms in 
enzyme molecules. Metal atoms play an important role in enzyme 
a c tiv ity  where they are thought to act as bridges fa c ilita t in g  electron 
transfer, such as must occur in the cata ly tic  formation or cleavage of 
any covalent bond. In cytochrome P-450, fo r example, an iron atom 
is chelated with pyrrole nitrogen atoms. Complexing o f the acetylene 
bond with such metal atoms might enhance enzymic reaction.
ACETYLENES IN NATURE
Acetylenic compounds are found in the plant kingdom, but not in 
the animal kingdom. In recent years the l i s t  o f known naturally  
occurring acetylenes has grown to more than 650. These have been 
isolated from many d ifferen t families of higher plants, algae, and 
micro-organisms (Bohlmann, Burkhardt and Zdero, 1973).
Several o f the natural acetylenes exhib it some powerful biological 
a c it iv it ie s , although re la tiv e ly  few seem to have been investigated. 
Acetylenes from fungi and higher plants often show a n tib io tic  a c tiv ity  
and indeed several plants exhib it increased production of anti-fungal 
acetylenes when infected with fungal pathogens (Allen and Thomas, 1971).
Some plant acetylenes are well known to be tox ic , fo r example the 
compounds from Cicuta v irosa  (water hemlock)c Some acetylenes have 
strong anti-fungal ac tiv ities  (cap illine  and related compounds) while 
others are used as antihelminths (some of the thiophenes, for example).
Several plants which have had a long history of use in medicine 
are known to contain acetylenes although no correlations o f the a c tiv itie s
of the acetylenes and the plant extracts have been made because of the 
d iffic u lty  in the preparation of the acetylenic compounds.
Although animals do not naturally produce acetylenes they are 
nevertheless exposed to a wide variety via foodstuffs derived from . 
plants. Very l i t t l e  is known about the way in which such compounds are 
metabolized or what effects they have on the animal metabolizing systems
.4 ACETYLENES AS DRUGS
Acetylenic groups have been incorporated into drugs for many 
years. Bock (1931) noted the hypnotic activ ity  of alkynols, and 
la ter Margolin (1951) reported acetylenic carbinols as hypnotics and 
sedatives. The l is t  of acetylenic drugs nowadays includes analgesics, 
anaesthetics, hypnotics, oncolytics, hypotensives, antibiotics, and 
the oral contraceptives (Figure 1.2}..
In general, acetylenic groups are introduced into drug molecules 
to enhance activ ity  per se by increasing the duration of pharmacological 
activ ity . The reasons for the increased activ ity  of acetylenes over 
the o lefin ic and saturated analogues are not well established but i t  may 
be connected with altered partition coefficients between lip id  and water 
This could influence the site of action or make the molecule more easily 
available to this s ite . In addition, increased bonding with proteins 
may be significant. The acetylenic group is electron rich, as are 
aromatic rings, and thus susceptible to bonding with receptor proteins. 
Acetylenic groups in drug molecules allow variation of the rest of the 
molecule without loss of the protein-bonding property.
Tt has been shown that trip le  bonds increase the surfactant 
character of a molecule appreciably when compared w/ith the unsaturated
Figure 1.2.  Structure o f 4-ethynylbiphenyl and examples 
of other acetylenic drugs
CeCH
4-EthynylBiphenyl
OCONH,
SfeCH
Etfrinimate'
HO
17a-Ethynyloestradiol
CH3 
.CH2{lCH2C=Ca
Pargyline
analogues (Leeds,.1965; Langecker, Schuman and Junkmann, 1953). I t  
seems reasonable to suspect that this property may well contribute to 
the enhancement of a c tiv ity  observed with some acetylenic drugs.
One of the reasons for the reduced to x ic ity  of acetylenic drugs 
over the corresponding o le fin ic  compounds may be due to the d iffe re n t  
distribution of Tr-electrons. I t  has been observed by Reisch and Walker 
(1964) that many Tr-electron compounds are carcinogens w h ils t polyacetylenes 
are n o t . ' ■. .
In some cases the value of the acetylenic group in a drug molecule 
is apparently due to its  being metabolically in ert protecting the drug 
molecule from metabolism (such as hydroxylation) a t an otherwise susceptible 
position. An important example o f this is seen in oral contraceptives.
The introduction of an acetylene group into oestradiol to produce 17a- 
ethynyl-oestradiol prevents the normal metabolic deactivation of oestradiol 
by hydroxylation to oestriol (Figure 1 .3 ) .  The h a lf - l i fe  o f the synthetic 
steroid is much greater than that of the natural hormone and the compound 
is widely used in oral contraceptive preparations0
STABILITY OF THE ETHYNYL GROUP
An extensive search through the available lite ra tu re  regarding 
acetylenic drugs shows that the ethynyl group is apparently very stable 
to metabolism. This applies equally to drugs containing terminal 
acetylenic groups and those in which the tr ip le  bond(s) is  part o f a 
side-chain and does not possess the s lig h tly  acidic acetylenic hydrogen. 
However, in many cases the published metabolic profiles of acetylenic  
drugs are not complete and the possib ility  exists that metabolism o f 
the ethynyl group does occur. In most cases, however, this would account 
fo r only a small percentage o f the metabolites.
Figure 1.3. Normal pathway o f oestradiol metabolism blocked 
~ "* by 1 l a -ethynyl a t i  o n
Oestradiol
17-oxido-
reductase
16a-hydroxylase HO
Oestrone
-OH
16a-Hydroxyoes trone
17 -o x i do red u c ta s e
Oestriol
-~C=Cli
No conversion to 
16a-hydroxylated 
metabolites
Ethynyloestradiol
An example of a widely used acetylenic drug with a terminal ethynyl 
group is the hypnotic drug ethinimate.
CONH
1-ethynylcyclohexyl carbamate (Ethinimate)
Ethinimate is characterised by rapid onset of action and short duration 
of sedation. Metabolism of the drug was found to be rapid (Swanson,
Anderson and Gibson, 1956), and these workers reported that no metabolites 
containing the acetylene group could be detected. I t  was speculated that 
rapid metabolism of the ethynyl group was responsible fo r the short action 
o f the drug. This was reinforced by the work of Perlman and Johnson*(1952) 
who found that methyl ethyl-ethynyl rcarbi no!, also a short acting hypnotic, 
was rapidly metabolised and no metabolites containing the ethynyl group 
could be detected. Both groups of workers however used as th e ir  determinant 
for the presence o f an acetylenic group, a metal reagent thought to form 
an insoluble metal s a lt with the tr ip le  bond. Later studies by McMahon 
(1958), however, indicated that a ll the metabolites o f ethinimate isolated  
contained the in tact ethynyl group and i t  was suggested that hydroxylation . 
of the cyclohexane ring was responsible for the fa ilu re  to detect the 
ethynyl group. I t  was then shown that hydroxyethinimate fa ile d  to give 
an Insoluble s ilv e r complex. I t  is worth remembering that formation o f 
insoluble, or soluble, salts is not a re liab le  diagnostic tes t fo r terminal 
acetylene groups.
METABOLISM OF ACETYLENIC COMPOUNDS
The metabolic conversion o f the acetylenic grouping in  animals has 
Been very l i t t l e  studied. The e a rlie s t reference is by Hoppe-Seyler (1882)
who reported the conversion of £-hitrophenylpropiolic acid to indoxyl. 
Bohm (1939) sim ilarly  found o-nitrophenylacetylene to be metabolized to 
indoxylo The mechanisms of these conversions are thought to be as 
illu s tra te d  in Figure 1*4.
El Masry, Smith and Williams (1958) studied the metabolism of 
phenyl acetylene in rabbits.
The only metabolites found were phenaceturic acid, the glycine conjugate 
of phenyl acetic acid, and inapdelfeacid, although the la t te r  was present 
in trace amounts only* The compound was found to be slowly metabolized, 
some 30-40% of the dose being eliminated in the expired a ir  unchanged 
over 3 days, and about the same amount was excreted in the urine over 
4 days as phenaceturic acid.
These findings were explained by the simple addition of water to 
the tr ip le  bond, although to explain the formation of phenyl acetic acid 
i t  was postulated that a hydroxyl group was added to the 3-carbon, that 
is , an asymmetric addition of water:
C=CH
Phenyl acetyl ene
H20
CH=CH°0H
: I
CH2»CH0
oxidation
Phenyl acetic acid
£-Nitrophenylpropiolic £-Nitrophenyl
acid acetylene
£-Hydroxylamino-phenyT 
ethylene
cyclization
- h2o
Indoxyl
hydroxylation
Indole
Figure 1*4 The metabolism of n-nitrophenylpropiolic acid
I f  symmetrical addition occurred then acetophenone and its  metabolites 
would have been expected:
' /  \v -C = C H
Phenyl acetylene
h2o
CCOH):CH2
Benzoic acid
•X'
Y vV—C“CHs
Acetophenone
I  \ CH(OH)*CH-
methyphenyl carbinol
CH-COOH
Mandelic acid
Except fo r traces of mandelic acid none o f the other metabolites were 
id e n tif ie d ,and so i t  was concluded that metabolism of the acetylene group 
proceeded by asymmetrical hydration.
This hydration does, however, contradict the general ru le mentioned 
e a rlie r , that substituted acetylenes add on water according to Markovnikov's 
rule;
RC=CH + H20 RC=CH,
OH
->- R-(j>CH- 
0
In another o f the rare references to ethynyl metabolism the addition 
of water to the tr ip le  bond of norethindrone was envisaged to occur via
a normal Markovnikov mechanism to give the 0 2 0  enolate of the 19-nor^- 
17~£s<?-progesterone which, in turn, could give rise to a 19~nor -173- 
hydroxy-iso-progesterone (Palmer, Feierabend, Bagget and Wall ,  1969).
Metabolism by
x g rabbit 
1iver supernatant
Norethindrone Estr-4-en-3,T7-dione
19-nor-'l 7-^so-progesterone
The metabolic removal of the 17a-ethynyl group from norethindrone 
represented the f i r s t  authenticated removal o f a steroidal 17a-ethynyl 
group. I t  is interesting to note that the A5^ 10^~isomer, norethynodrel 
is not metabolised in this way, but instead to 3a— and 33— hydroxy 
derivatives;
3a~hydroxy isomer R=OH ; 
33-hydroxy . isomer R=H R -  aH;
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E arlier workers had detected metabolism of 17-ethynyl groups 
in steroids, for example, Kamyab, L ittle ton  and Fotherby (1967) 
demonstrated that 136-ethyl-17a-ethynyl-176-hydrogen-4-en-3-one 
(Norgestrel) when labelled with in the ethynyl group gave rise  
to small amounts (0.6% -  0.9%) o f dose in expired a ir  o f rabbits.
In this and other studies (Fotherby e t  a l91966; De Jongh e t a i9 1968) 
where minor metabolism of the 17-ethynyl group was found the products 
and intermediates were not id en tified .
1.7 METABOLISM OF ARYLACETIC ACIDS
Aromatic and aryl alkyl carboxylic acids frequently undergo 
metabolic conjugation before excretion. Such conjugation can be with 
a carbohydrate, which in mammals is usually glucuronic acid, or with 
amino acids. Among mammalian species the amino acids are usually 
glycine, glutamine or taurine, depending on species.
The conjugation of these acids presents many good examples o f 
species differences in phase I I  o f dn?g metabolism. Both types of conjugation 
often form competing metabolic pathways and factors related to species 
difference appear to be o f great importance in determining the route o f  
conjugation. For example, the excretion of benzoyl glucuronide as an 
important metabolite o f benzoic acid has been observed in four species 
only, notably the dog (Bridges e t  al> 1970).
glucuronic
acid
Benzoyl glucuronide
Benzoic acid
Hippuric acid
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The conjugation o f benzoic acid with glycine to give benzoyl-  
glycine (hippuric acid) was detected in man and other species more 
than a century ago ( Keller, 1842) and is the major metabolite in 
man and many mammals, particu larly  the herbivorous species.
In view of the known conjugation pattern of benzoic acid i t  is 
interesting to note that s ign ificant amounts of the acyl glucuronide 
of 2“ (4 l -carboxystyryl)~5“n itro -T“Vinylimidazole were produced in 
rodents, the glycine conjugate being a minor metabolite (Morton, 
Fuller and Green, 1973).
S im ilarly , the glucuronide of niflumic acid was the major metabolite 
of the drug in man and dog (Lan e t  a l 9 1973).
ch=ch2
COOH
2- (4 ‘ -carboxystyryl)-5-nitro-1-vinylim idazole
Niflumic acid
CF,
3
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The metabolism of these two compounds, in which the carboxylic 
acid group is attached to a . large molecular structure rather than 
a single benzene ring, suggests that in addition to species differences 
the physical and chemical"properties of an aromatic acid are key 
factors in phase I I  metabolism. Despite the considerable amount of 
investigation into aromatic and aryl alkyl acid metabolism the nature 
o f these factors remains unknown. Very recent v/ork by Dixon, Caldwell 
and Smith (1977a,b,c) has given a better understanding o f the physical 
and chemical properties that are important in determining whether a 
compound is conjugated with an amino acid or glucuronic acid. These 
workers have correlated the structures o f phenylacetic acid, 1-naphthy1- 
acetic acid, hydratropic acid and diphenyl acetic acid with observed 
conjugation patterns, and presented evidence that the pattern o f 
conjugation was structure dependent.
Phenylacetic acid and its  simple ring substituted derivatives 
have been shown to be conjugated mainly with amino acids (dames, e t  a l 3 
1972). In man the amino acid used for conjugation has been id en tified  
as glutamine (Thierfelder and Sherwin, 1914, 1915) w h ilst in  most other 
species glycine is u tilize d  (as for benzoic ac id ).
Dixon e t a l.  (1977) found that w hilst 1-naphthylacetic acid was 
conjugated with both glucuronic acid and amino acids, hydratropic and 
diphenyl acetic acid were conjugated with glucuronic acid. I t  seems 
that the chemical structure of the acids was important in determining 
the binding characteristics with the endoplasmic reticulum and 
mitochondria, the major sites o f glucuronic acid and amino acid 
conjugation respectively. The actual structure rather than the lip id
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s o lu b ility  seemed to be the directing factor. Hansch (1972) and others 
have suggested that the lip id  so lub ility  o f a compound is the major 
determinant for metabolism in the endoplasmic reticulum (microsomes 
in in  v i t r o  systems) -  the s ite  of glucuronic acid conjugation. With 
the aryl acetic acids and th e ir derivatives the lip id  s o lu b ility , as 
determined by partitio n  coefficients in w ater/lip id  i n  v i t r o  systems, 
cannot be used successfully to predict the direction of conjugation. 
Obviously, the sites of conjugation with glycine and glucuronic acid 
impose d iffe ren t lim itations on the chemical structure of the acids 
able to in teract a t these s ite s .
BILIARY EXCRETION OF ORGANIC COMPOUNDS
The two most important routes of excretion of most organic 
compounds, endogenous or exogenous, are the urine and b i l e .  In  a few 
cases other routes may be of greater significance, fo r example the 
elimination in the expired a ir  of vo la tile  compounds such as benzene 
(Parke, 1968) and the secretion of some ionizable compounds from the 
plasma into the gastro-intestinal tra c t.
A compound may be eliminated either in urine or .b i l e ,  or in both, 
the actual route and re la tive  amounts o f excretion depending on several 
factors. These factors include species difference, the chemical and 
physical nature o f the compound, molecular weight, and route o f 
administration. The excretion of a drug or its  metabolites in the 
bi le has several important implications. The eventual fate o f compounds 
is subject to a variety o f factors which may influence the overall 
excretion pattern and perhaps metabolism. Metabolites secreted into the 
b ile  may be further metabolized in the gut and so appear changed in the
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faeces: they might be reabsorbed from the gut and undergo enterohepatic 
circu lation , further metabolism by the liv e r  or in testinal wall 
eventually producing metabolites that appear in the urine rather than 
the faeces.
Another mechanism that can cause prolonged drug elimination is the 
coprophagic habit of some animals, especially rodents. This can be 
particu larly  important when comparing excretion times o f drugs excreted 
predominantly in the faeces in coprophagic and non-coprophagic animals, 
such as ra t and man respectively.
In view of these possib ilities  and also species differences which 
govern them, i t  is of prime importance to ascertain the role of b ilia ry  
excretion when considering the metabolic fa te  and toxicological aspects 
of drugs and xenobiotics.
1 .8 . i MOLECULAR WEIGHT REQUIREMENTS AND SPECIES DIFFERENCES IN BILIARY EXCRETION
Two very important factors determine the excretion of organic 
compounds in the b ile . These are molecular weight and p o la rity . Compounds 
with a high molecular weight (above 500) possessing a polar grouping such 
that the molecule is an anion a t the alkaline pH of b ile , tend to be 
extensively excreted in the b ile  of most species (see review by M illburn, 
1970).
The significance of the molecular weight of a compound is not c lear, 
although i t  is an indication of the molecular s ize . The properties 
necessary for s ign ificant or extensive b ilia ry  excretion have been 
investigated by a number of workers and a wide variety o f compounds studied. 
Much of the work has been performed on the ra t because o f the re la tive  
ease and convenience o f using this species, although other species have
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been studied to investigate aspects of species differences.
A study of the b ilia ry  excretion in ra t ,  o f over 20 benzene
derivatives with molecular weights less than 300 (Abou El-Makarem,
e t  a l j  1967a) has shown that these compounds were poorly excreted
in the b ile . The conjugates produced were acidic, pK 3-5, and anionsa
a t pH 7 .4 , but were largely excreted in the urine (>90% ).
Compounds containing two or more aromatic rings were, however, 
extensively excreted in the b ile  of rats ( Mi 11 burn, Smith and 
Williams, 1967).,f The glucuronic acid conjugates of 4-hydroxy- 
biphenyl and 4 -4 '-dihydroxybiphenyl were excreted in appreciable 
amounts (65% and 59% respectively). These carboxylic acid glucuronides 
have a molecular weight of about 350 and thus ex ist as anions in the 
b ile . /
In studies using other species a sim ilar pattern was observed 
(reviewed by Millburn, 1970). Compounds of low molecular weight 
(less than 300) are poorly excreted in the b ile  of ra t, dog, hen, cat, 
sheep, rabb it, guinea-pig, rhesus monkey, and probably man.
Studies using non-metabolized compounds with molecular weights 
between 300-500 (Abou El-Makarem, e t  ol> 1967b; Davison and Williams,
1968) have been used to compare b ilia ry  excretion between species. I t  
is possible to classify various species into groups of good or poor 
b ilia ry  excretors. In the f i r s t  of these categories are found the ra t, 
dog, and hen w hilst in the second are rabbit, guinea-pig,and rhesus 
monkey. Man seems to be in this la t te r  classe
An extensive study o f molecular weight thresholds in r a t ,  guinea-pig
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and rabb it with a large number of organic compounds gave quite well 
defined values (Hirom, e t  a l9\§ l t ) +  These were determined as 325 + 50 
for the ra t, 440 +_ 50. for the guinea-pig, and 475 + 50 for the rabbits
Many commonly used drugs fa ll  within this molecular weight range, 
a fact emphasising the need for caution in relating the results o f 
animal tr ia ls  to mane Organic anionic compounds with molecular weights 
above 500-600 are extensively excreted (greater than 40% o f dose) in  
most species,
108 . i i  EFFECTS OF. SPECIES DIFFERENCE IN METABOLISM
Many organic xenobiotics do not possess the properties to be 
b ilia ry  excreted un til they have undergone phase I or phase I I  
metabolism. Most compounds that appear in the b ile  are conjugates, 
usually glucuronides and sulphates. A good example, of how metabolism 
affects b ilia ry  excretion is that o f biphenyl:
Biphenyl
4-Hydroxy biphenyl
V  \ y - / /  \ V _ 0 -C  H6"9°6
I 4-Glucuronosidobiphenyl
Phase I 
oxidation
4 ' ,4-Dihydroxy biphenyl
COO
Phase I I
conjugation with 
glucuronic acid
HO
I I  4 -Glucuronosido-41-hydroxy-
biphenyl
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Biphenyl (low molecular weight, non-polar m olecule)is  metabolised 
to glucuronides o f the phenolic metabolites, I and I I ,  which have 
molecular weights of 346 and 362 respectively. Species differences 
in the metabolism of drugs^and xenobiotics are well known (Williams, 1967; 
Smith, 1968; Parke, 1968). These differences can be responsible for 
many of the observed differences in b ilia ry  excretion. For example, in 
the metabolism of aryl acetic acids and derivatives, the difference between 
conjugation with glucuronic acid or with glycine makes a difference in 
molecular weight of over 100 and so can drastica lly  a lte r  the route
of excretion. 1
> • • _
1 .8 . i i i  ENTERQHEPATIC RECIRCULATION
Foreign compounds are excreted in the b ile  mainly in the form of 
conjugates such as glucuronides and sulphates. Once these are secreted 
into the b ile  they are lia b le  to hydrolysis (deconjugation) by enzymes 
present in the b ile  (S later and G r iffith s , 1965), or more lik e ly , the 
intestine by enzymes produced either in the intestinal wall or by gut 
microflora (Smith, 1966; Scheline, 1968).
Thus in many cases, conjugates are not excreted in the faeces, instead 
they undergo hydrolysis by the action o f enzymes such as 3-glucuronidase 
or a sulphatase and the free compound is iiberated0 The free metabolite 
so produced may be reabsorbed whereupon i t  is passed to the l iv e r  and may 
be conjugated again or undergo further phase I metabolism followed by 
conjugation and excretion in the b ile  (a lternative ly  the reabsorbed metabolite 
may be excreted in the urine). The cyclic process thus set up is known as 
enterohepatic recirculation.
The consequences of the process are several-fold 'and very important
in the consideration of patterns o f excretion and metabolism o f foreign 
compounds. The f i r s t  and most obvious result is prolonged retention 
in the body and extended h a lf-lives  (also caused by localiza tion  o f a 
drug in a particu lar tissue, such as adipose tissue)* The implication 
of this is important and can influence the to x ic ity  of a drug. In the 
case o f irr ita n ts  or ulcerogens of the upper gastro-intestinal trac t the 
continued cycling of toxic metabolites can increase the degree of damage 
sustained. Another result o f enterohepatic recirculation is the 
appearance in the urine o f metabolites produced by the gut microflora 
or in testinal wall (Smith, 1966), these arising from the metabolism of 
deconjugated compounds that are subsequently reabsorbed and excreted 
at the kidney. Thus, in the metabolism of chloramphenicol (Glazko, D ill 
and Wolf, 1952) the free nitror-group o f the deconjugated drug was reduced by 
gut microflora and the resulting amines excreted in both urine and faeces. 
B ilia ry  excretion o f chloramphenicol was very low in man, however, and 
the reduced metabolites were not observed, clearly demonstrating the 
importance o f species variation. As well as differences in extent o f 
b ilia ry  excretion the gastro-intestinal environment ('pH, m o til ity *’ tra n s it v 
time, etc) and microflora population can vary between species.
An example o f how the enterohepatic recirculation process can be 
useful is in the metabolism of the contraceptive ethynyl-steroids. These 
compounds are extensively recycled and depend upon this fo r the 
re la tive ly  long h a lf-lives  compared to the natural steroids.
1.9 THE INFLAMMATORY REACTION AND INFLAMMATORY DISEASES
Inflammatory diseases, sometimes known as "connective tissue
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diseases" because the primary sites of action are the connective v
tissues of the jo in ts , tendons, bones, and heart, include rheumatoid 
a r th r it is , rheumatic fever, osteoarth ritis , lupus erythematosus and 
ankylosing spondylitis. These a r th r it ic  and rheumatic diseases; are  
second only to heart diseases as the major cause of physical 
d is a b ility  and chronic lim ita tion  of physical a c tiv ity .
The inflammatory process is an extremely complex and poorly 
understood phenomenon. Known mediators of the acute inflammatory 
reactions include histamine, serotonin, kinins, and more recently 
many other endogenous substances have been implicated in the m ultiple  
mechanisms of the inflammatory process. The la t te r  include lysosomal 
enzymes (De Duve, 1964; Weissman., 1966) and prostaglandins (see Vane, 
1971; C o llie r, 1971; Pharris and Ramwell, 1972). A general approach 
to the treatment o f inflammatory disease has been the development o f 
drugs with a b ilit ie s  to in h ib it or suppress the known mediators. I t  is 
interesting that many selective mediator inhibitors such as, 2 ,4 -d in itro -  
phenol and dicumarol, have not proved useful as anti-inflammatory agents, 
but most c lin ic a lly  active non-steroidal anti-inflammatory drugs in h ib it  
some of the mechanisms involved in the release or action o f one or more 
mediators.
1.10 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
There has been considerable in terest in the past 15-20 years in  
producing non-steroidal anti-inflammatory drugs in an attempt to produce 
c lin ic a lly  effective alternatives to the glucocorticoids but lacking the 
undesirable si de-effects of these la t te r  compounds. The resu lt is  a 
wealth o f compounds with claimed anti-inflammatory properties and with
a wide diversity o f structure. Correlation of structure to ac tiv ity  
has proved very d if f ic u lt  and such correlations, though helpful in 
one series of active compounds, are not usually transferable to other 
series. Many o f the non-steroidal anti-inflammatory agents also 
possess an ti-pyretic  and analgesic ac tiv ity  (useful in the case of 
rheumatoid a r th r it is , for example) and i t  is only re la tive ly  recently 
that specific biological and i n  v i t r o  tests have been developed to 
distinguish a specific anti-inflammatory component from other properties.
One important class of non-steroidal anti-inflammatory agents 
comprises a wide variety of aromatic acid derivatives, such as those 
shown in Figure 1 .5 . Several drugs have been developed with structures 
sim ilar to these compounds but without an acidic grouping in an attempt 
to obtain anti-inflammatory agents with reduced si de-effects (especially  
gastric ir r ita t io n )  which is common with the aromatic and aryl alkyl 
acids.
Some of the acidic compounds in this series share common properties 
which are used to predict anti-inflammatory agents. For example, the 
uncoupling of oxidative phosphorylation and the inhib ition o f prostaglandin 
synthesis. Although a s ignificant correlation can be made, between an ti­
inflammatory and anti-rheumatic a c tiv ities  o f non-steroidal an ti-  
inflammatory drugs with th e ir  a b ility  to uncouple oxidative phosphorylation 
(Adams and Cobb, 1958; Whitehouse, 1965; Whitehouse and Skidmore, 1965), 
i t  is a rather general and non-specific test and compounds other than 
anti-inflammatory agents are uncouplers (Adams and Cobb, 1958; Domenjoz, 
1966).
The finding that acidic anti-inflammatory drugs inhibited the synthesis 
of prostaglandins (Ferreira 1971;Angaard and Samuelsson, 1965; Piper and
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Figure 1 .5 . Some examples .of acidic non-steroidal anti-inflammatory drugs
CH-COOH
0
Fenoproferr
■N' > N  
I
H
Niflumic acid COOH
Clonoxin
?2H5
CH -O'-CH -CH-COOH 
2 2 2
ropronic acid
Vane, 1971} renewed in terest in these drugs. The role o f prostaglandins 
in the inflammatory reaction, although not clear, has received much 
attention in recent years. The inhib ition of prostaglandin synthetase 
is the basis of an important in  v i t r o  test for anti-inflammatory drugs.
non- .
Biphenylylacetic acid belongs to the aromatic class of^steroidal 
anti - i nfl ammatory agents.
An undesirable s ide-effect shared by many o f these acidic agents 
is th e ir  damaging action on the upper gastro-intestinal tra c t where 
severe ir r ita t io n  or ulceration is often produced. The mechanisms by 
which these' drugs exert th e ir destructive effects are not c learly  
understood but several theories have been forwarded. One suggested 
mechanism is that the drugs influence blood p la te le t function leading 
to an increased susceptib ility to gastrointestinal bleeding. This has 
been particu larly  well studied with respect to aspirin (Hirsch and Doery, 
1971; Holmsen, Day and Stormorken, 1969; Mi 11s, e t a l9 1974). Another 
more recent suggestion is their inhibitory action on prostaglandin 
synthesis. Prostaglandins have been shown in rat to in h ib it  gastric  
and duodenal ulcer formation induced by a variety o f compounds (Robert, 
Nezamis and P h illip s , 1967; Robert, Stowe and Nezamis, 1968). Main 
and W hittle (1973) showed that prostaglandins of the E and A series 
caused a s ign ifican t increase in the mucosal blood flow and clearance 
rate , possibly acting as a negative feedback inh ib ition  on acid secretion.
I t  is interesting to note that the inhibitory e ffe c t of a n ti­
inflammatory agents on prostaglandin synthesis can be used to explain 
both the desired action of these drugs (a reduction in the manifestations 
o f the inflammatory reaction) and one of the main side effects (ulceration  
o f the gastro-intestinal tra c t) . The type of action that endogenous
prostaglandins display is dependent, upon th e ir concentration, they can 
display to ta lly  opposite effects a t d iffe ren t concentrations (Horton, 
1969; Ramwell and Shaw, 1971; Anderson and Speroff, 1971).
Another way in which some anti-inflammatory drugs are thought to 
bring about ulceration is by reducing the effectiveness of the protective 
mucus barrier of the gastro-intestinal tra c t. This e ffec t could be 
caused by alterations to the mucus-producing cel 1 s resulting in an 
inh ib ition  of mucus production or production of a less e ffec tive  mucus. 
The e ffec t of known ulcerogenic agents on the synthesis o f the glyco­
proteins and sulphoglycoproteins o f mucus has been investigated by 
several workers. The inh ib ition  o f such synthesis was f i r s t  investigated 
with salicylates (Kent and Allen, 1968; Lukie and Forstner, 1972).
1.11 METABOLISM OF BIPHENYL
In considering the lik e ly  routes of metabolism of 4-ethynyl 
biphenyl the molecule can conveniently be divided into two sections, 
the ethynyl group and the biphenyl molecule. The metabolism o f the 
la t te r ,  unlike that o f acetylenes, has been widely studied (K1ingenberg, 
1891; West e t  a l9 1956; Creaven, Parke and Williams, 1964, 1965; Raig 
and Ammon, 1970, 1972; Meyer and Scheline, 1976a, b, c, 1977a, b ).
The various metabolites of biphenyl are summarised in Figure 1 .5 .
The oxidation of aromatic compounds to phenolic metabolites is 
probably the most widely studied biotransformation and has been well 
reviewed (Daly, Jerina and Witkop, 1972). The usual products of the 
oxidation o f an aromatic ring, including those of the biphenyl molecule, 
are phenols and catechols. The mechanism of the reaction seems to be 
as illu s tra ted  in Figure 1.6 . The decisive breakthrough in the
Figure 1 .6 . Some of the known metabolites of biphenyl
Biphenyl
Epoxide intermediate
4-hydroxybiphenyl
( /  \ W  V ^ C H . c-COOH  
\ = = /  \ = = /  HNC0CH3
4 -biphenylylmercapturic acid
4 ' ,4 - dihydroxybiphenyl
3-hydroxybiphenyl
4-hydroxy-3 methoxybiphenyl
2-hydroxybiphenyl
3-'hydroxy-4-methoxybi phenyl
3 ,4-dihydroxybiphenyl
determination of this mechanism came in 1968 (Jerina, e t a'Z> 1.969)' 
when naphthalene-1, 2-oxide was identified  i n v i t r o  as the obligatory 
intermediate in the oxidation metabolic pathways of naphthalene.
Such arene oxides have since been identified  in other metabolic 
transformations and ittacvsbeen shown that the direction o f the ir  
further metabolism depends on th e ir re lative s ta b il ity . For example, 
for conjugation with glutaihjone to occur, to eventually produce pre- 
mercapturic and mercapturic acids, the arene oxide must be re la tive ly  
stable and not undergo spontaneous non-enzymic isomerization to the 
phenol. An enzymic reaction of the oxide is the hydrolytic cleavage 
of the epoxide ring by -epoxide hydrases to the dihydrodiol o f the 
trans-configuration* The intermediate arene oxide probably does not 
have to be so stable to undergo this la t te r  reaction as the epoxide 
hydrase a c tiv ity  is thought to be closely associated with the endo­
plasmic reticulum mono-oxygenase system (Oesch, Jerina and Daly, 1971; 
Nebert e t  t i l *  1972; Oesch e t t i l * 1972).
All the phase I metabolites o f biphenyl are produced by the above 
mechanisms. The excretion products are a ll  phenols or th e ir  conjugation 
products with sulphate, glucuronic acid, or glutathione (Block and 
Cornish, 1959; West e t  t i l *  1956).
The f i r s t  metabolic experiment with biphenyl was performed by 
Klingenberg (1891) and since then the metabolism of the compound has 
been studied in a variety of species, both i n  viv&  and in  v i t r o . 
Klingenberg showed that in the dog biphenyl was metabolised to 4-hydroxy 
biphenyl. The same biotransformation was la te r  demonstrated in the 
rabbit (Stroud, 1940; Block and Cornish, 1959). Similar experiments 
in the ra t revealed a variety of metabolites of which 4-hydroxy, 4 ' ,4 - 
dihydroxy, and 3,4-dihydroxybiphenyl were isolated by West e t t i l .
(1953, 1955, 1955). These compounds form the major metabolites in 
most species but more sensitive analysis by gas-chromatography and 
fluorim etry has enabled the isolation and id en tifica tion  of other . 
metabolites such as 2- hydroxy biphenyl and la te r 3-hydroxy biphenyl 
(Raig and Ammon, 1970) and the two mono-methylated derivatives of the 
3 ,4-dihydroxy metabolites (Raig and Ammon, 1972).
The metabolic conversion of biphenyl has been studied i n  v i t r o  
using animal liv e r  preparations (Creaven, Parke and Williams, 1955).
In this study, the metabolism of biphenyl was investigated in  eleven 
species and i t  was found that the extent and type of hydroxylation 
was species dependent.
-Although many studies of the in  v ivo  metabolism of biphenyl have 
been performed and the q u a lta tiv e  aspects are clear, there has been 
a lack of good qualitative studies using radio-isotopically  labelled  
biphenyl. A comparison of the various results published is not always 
easy because workers have used d ifferen t dose levels and d iffe ren t 
routes of administration. There is also the additional factor that the 
age of the experimental animal is important in determining the re la tiv e , 
amounts of the various phenols produced (Creaven, Parke and Williams, 
1965).
Most workers have found that 4-hydroxy biphenyl is the major 
metabolite in various species, dog (Klingenberg, 1891), rabbits (Stroud, 
1940: Block and Cornish, 1959; Raig and Ammon, 1970, 1972), mice (Creaven 
and Parke, 1966), pigs (Meyer, Larsen, Hansen and Scheline, 1976), and 
rats (West, e t a la 1956). Recent studies obtained by Meyer and Scheline 
(_!975b) in the rat indicated that 4 1,4-dihydroxy biphenyl was the major 
metabolite. These workers, however, only recovered a to ta l of 34% of the 
administered dose and were using unlabelled biphenyl.
B ilia ry  excretion of the conjugated phenolic metabolites of 
biphenyl has been demonstrated (Mi 11 burn, Smith and Williams, 1967;
Levine, e t a ls 1970; Meyer and Scheline, 1976a,b,c), and faecal excretion 
of these metabolites observed. The re la tive  amounts of excretion in 
faeces or urine reported varied widely and there has not been a 
good investigation into enterohepatic recirculation of biphenyl 
metabolites or the contribution to the metabolism of biphenyl made 
by gut m icroflora, i f  any.
.12 AIMS OF THE PROJECT
A fu ll investigation into the metabolic fa te  of 4-ethynylbiphenyl , 
w ill be undertaken. This would fa c il ita te  the elucidation of the 
mechanisms by which the drug exerted its  observed actions i n  v ivo  , 
namely its  anti-inflammatory a c tiv ity  and its  undesired si de-effects  
of gastric ir r ita t io n  and ulceration as noted in the ra t and dog. Any 
novel metabolites found might possess good anti-inflammatory characteristics  
without the damaging side effects of the parent drug.
In addition, the possible metabolism of the ethynyl group was 
extremely interesting in view of the use of this group in  many drugs, 
notably the contraceptive steroids and paucity of published information 
regarding acetylene metabolism in animals.
CHAPTER TWO
THE SYNTHESIS OF 4- [ llf C]ETHYNYLBIPHENYL AND TWO OF ITS METABOLITES
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2 j  SYNTHESIS OF ;4-[^C]ETHYNYLB.IPHENYL
The synthesis of ^-(^CJethynylbiphenyl was performed using 
1 - [14C]-acetyl chloride as the source of radioisotope. The product was 
labelled as below:
Two methods of synthesis were used.
Materials
1 - [1^C]-4-Acetyl chloride (2.5 mCi/mmole) was purchased from the 
Radiochemical Centre, Amersham. All other chemicals were standard 
laboratory reagents of Analar grade. Phosphorous pentachloride and 
aluminium trich loride were subliimed before use, and acetyl chloride was 
re d is tille d  before use.
The in it ia l  batch of radiolabelled 4-ethynylbiphenyl was produced 
using a semi-micro scale-down of a synthesis used by Allen and Hanbury 
Ltd (unpublished) to prepare the unlabelled drug on a large scale. This 
is out!ined below.
C=14CH
4 - [ 14 C] £-j-^ y ny ] b i ph e ny 1
2.1 . i  METHOD I
Biphenyl
I A1C13/C H 3C0C1
Y
CH=CHC1 4-Chlorovi nylbi phenyl
I I I KOH [alcoholic)
F A - f \ 4-Ethynylbi phenyl
Because of the small scale envisaged for the radioactive synthesis 
[0 .5g -l .5g) and the considerable cost of [ llfC]-acetyl chloride i t  was 
important to achieve maximum efficiency and r e l ia b i l i ty .  Many 'cold ' 
syntheses were therefore carried out to determine optimum reaction mixtures, 
temperatures, times and vessels.
a). Reaction 1 Synthesis _of_ 4-aoetyVpiphemjZ
This in it ia l  step was a straightforward Friedel-Crafts reaction in 
which the acetyl function of the acetyl chloride was para-substituted in  
the biphenyl molecule. In i t ia l ly ,  using amounts of reagents scaled down 
from the large scale preparation, yields on the semi-micro scale were poor 
[< 60%). This problem was overcome by using s lig h tly  more than stoichiometric 
amounts of the d4c*trophil ic catalyst aluminium trich lo rid e . This was
because the product of the reaction being a ketone and weakly basic was 
able to in h ib it the reaction in two ways. F irs tly , by complexing with 
the catalyst as i t  was formed:
I t
thereby removing the la t te r  from further participation in the reaction. 
Secondly, i t  could complex with the acyliurn ion, preventing i t  from 
attacking the aromatic ring (Ar}:
I t  was found that for optimum efficiency ( > 90%) the amount of 
catalyst (freshly sublimed) was c r it ic a l.
Anhydrous aluminium chloride (1.5g, 11 mmol) was suspended in 
dichloromethane (7.5 ml, dried over a molecular sieve) in a round 
bottomed, two-necked, 50 ml flask. The suspension was kept s tirred  
using a magnetic s t ir re r  and heated gently (o il-b a th , 60-70°C) to reflux
0 0
li « + >- Ar-C=0: A1C13CH3-C -C I: A1C13 — ^CH3- r  A1CU
+ HC1
ArCOCH
/A r +
A1 Cl ^
Acetyl chloride [0.8g, 11 mmole) and biphenyl (.154g, 10 mmol, 
recrystallised from ethanol) were dissolved in dichloromethane (5.0 ml) 
and added to the rapidly s tirr in g  suspension over a period of 20 min 
(dropping-funnel) .  There was evolution of HC1 gas and the mixture 
became deep red/purple in colour. The reaction was refluxed for a further 
1 ,75h (60-70°C).
The progress of the reaction was followed using th in -layer chromatography 
[s ilic a  gel plastic backed 5 x 10 cm plates, toluene (5%) and petroleum 
ether 60-80 ( 95%) as the solvent system], 4-acetyl biphenyl had an Rp. = 0 .6 ,
biphenyl ari R = 0.95.
... f
When the reaction was complete the solvent was removed by d is t il la t io n  
under reduced pressure and the residue hydrolysed by the addition of ice-cold  
hydrochloric acid (2M, 100 m l). The yellowish-white residue of the hydrolysis 
was f i  1 tered o ff and recrystal 1 ised from ethanol to give a white product, 
m.p. 116-n9°C ( l i t .  119-120°), yie ld  1 .5 -1 .6g (80-907).
I t  was necessary to purify this product by sublimation prior to the 
next step, to prevent the formation of a dark resinous material upon reaction 
with phosphorus, pentachloride. This was possibly the resu lt o f polymerization 
of the vinylchloride upon formation, in itia te d  by the presence of traces o f 
aluminium. This problem was not encountered when preparing larger amounts 
[> lOg) of 4-acetyl biphenyl.
Sublimation was performed under reduced pressure (oil-pump) a t 130-140°C 
[o il-b a th ). The y ie ld  was 90-95%. A diagram of the sublimation apparatus 
is shown in Fig. 2 .1 .
The product of the sublimation was a white m icro-crystal!ine powder 
melting a t 119-120°C.
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Figure 2 .1 . Sublimation apparatus
W at er iri
W afe r o u t
Vacuum
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b) R eaction I I  P repara tion  o f  4 -cK lo rov iny  Ib iphenyt
This hydrohalogehation step was accomplished.using phosphorus 
pentachloride with toluene.as the solvent.
4-Acetyl biphenyl (1.96g, 10 mmole), phsophorus pentachloride 
(2.4g, 13 mmole) and toluene (8 .0 ml) were stirred  in a one-necked9 50 
ml round bottomed flask using a magnetic s t ir re r . The reaction mixture 
was heated gently (o il-bath ) until the reaction commenced, usually at 
about 45°C, with the evolution of HC1 gas. The temperature rose 
spontaneously to 50-55°C and was maintained at this level fo r 45 min, 
or until evolution of HC1 had ceased. The temperature was then slowly 
increased with s tirrin g  to 100°C and maintained for Ih . A fter this 
time the toluene and phosphorus, oxychloride were removed by d is t il la t io n  
under reduced pressure (70°C). the flask containing a grey/brown residue 
was cooled in. ice and ethanol (3.0 ml) added to remove any remaining 
oxychloride. This was le f t  to stand for 30 min and the mixture then 
f ilte re d  a t the pump.
Upon recrystallisation p-chlorovinylbiphenyl was produced as a pale 
grey/brown m aterial, m.p. 116-118°C, y ie ld  1 .1 -1 .3g (65-75%).
c ) R eaction I I I  P repara tion  o f  4-ethywylbiphercyt
This dehydrohalogenation step was performed using strong alocholic 
potassium hydroxide solution.
4-Chlorovinylbiphenyl (l.Og, 4.9 mmol) was added to a rapidly  
s tirr in g  solution of potassium hydroxide in ethanol (30%, 16 ml) in a 
one-necked 50 ml flask with condenser. The mixture turned brick-red  
in colour and gradually darkened. The flask was heated (o il-b a th ) to 
maintain a reflux and the reaction progress monitored every 10 min. by
thinrrlayer chromatography using the method described e a rlie r . Ethynyl-■
biphenyl had an R^  of 0.65 and _p-chlorovinylbiphenyl an R^  o f 0.45.
I t  was important to monitor the reaction progress carefully to avoid the
formation of impurities which showed on th in-layer chromatography as spots
with R  ^ values between 0 .5 -0 .6 . f
At the f i r s t  appearance of these^impurities the reaction was stopped 
by pouring the reaction mixture into cold water (200 m l). The salmon- 
pink suspension was extracted with ethyl acetate (6 x 10 m l), the combined 
extracts washed with water (4 x 100 ml) and dried over anhydrous magnesium 
sulphate. The product was concentrated by rotary evaporation under reduced 
pressure.
The yellowish residue was purified by sublimation (apparatus as described 
e a rlie r) under reduced pressure a t 100-1!0°C.
The 4-ethynylbiphenyl produced was a white m icro-crystalline material 
which was recrystallised from methanol to produce white plates (210-230 mg 
35-40 % y ie ld ) m.p. 88-89°C. (Overall y ie ld  for synthesis 12-15%).
The in i t ia l  reaction to produce 4-acetyl biphenyl was performed as 
before. The conversion of the 4-acetyl biphenyl to 4-ethynylbiphenyl was 
achieved in one step, eliminating the need to isolate and purify in te r ­
mediates :
2.1 . i i  METHOD I I
C0CH3 pyridine
50°C
PCI 5
CH
4-Acetyl biphenyl 4-Ethynylbi phenyl
Standard laboratory reagents were used, the pyridine being dried over 
a molecular sieve.
Freshly sublimed phosphorus: pentachloride (4.2g, 20 mmol) was used 
immediately a fte r  weighing out into a stoppered vessel. This was added 
to pyridine (15 ml) in a 50 ml, round bottomed, one-necked flask equipped 
with an air-condenser and a drying tube. The solution was heated to 50°C 
(o il-b ath ) and stirred  using a magnetic s t ir re r . 4-Acetyl biphenyl 
(0.784g, 4 mmol), dissolved in dry pyridine (15 m l), was added quickly 
and s tirrin g  continued at 50°C for about 3h or until th in -layer  
chromatography [s ilica -ge l plastic.backed plates, 5 x 10 cm, cyclohexane: 
ethyl acetate (3 :1 )] indicated the completion of the reaction, - f f R f  
Values fo r h -  ac\  ^ o*3€ .
The reaction mixture was poured onto ice (about 5g) to which hydrochloric 
acid (2M, 30 ml) had been added. This was extracted with petroleum ether 
(b .p . 40°-60°C, 6 x 20 m l). The combined organic extracts were washed with 
d ilu te  hydrochloric acid (2M, 3 x 75 ml) to remove remaining traces of 
pyridine, water (3 x 75 ml) , saturated sodium chloride solution (75 ml) 
and dried over anhydrous magnesium sulphate. The solution was f i l te r e d ,  
the magnesium sulphate washed with ether and the combined f i l t r a te s  con­
centrated under reduced pressure. The residue was dissolved in a l i t t l e  
ether and the solution concentrated again to help remove the la s t traces of 
petroleum ether. This produced a yellow-white solid (0.40-0.43g, 56-61% y ie ld )  
which was dissolved in the minimum amount of ethyl acetate (2-3 ml) and 
diluted with petroleum ether (60°-80° b .p .) to about 5 ml and purified by 
chromatography on a s ilic a  gel column (2 cm x 35 cm, s ilic a  gel 70-230 mesh) 
using petroleum ether (60°-80° b .p .) toluene (95:5) as eluant. Fractions 
of 20 ml were collected and those affording the 4-ethynylbiphenyl as a 
single spot were combined and concentrated under reduced pressure to give
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a pale yellowish so lid . This was recrystallised from methanol-water 
(80:201 to produce white needles which were filte re d  o f f ,  washed with 
the minimum amount of aqueous methanol and dried in  vacuo at room 
temperature. The 4-ethynylbiphenyl thus produced had an m.p. o f 88-89°C, 
and gave no depression of the m.p. when mixed with authentic 4-ethynylbiphenyl. 
Yield 200-210 mg (36-40% y ie ld ) .
The overall y ie ld  of the synthesis was 23-25I  (c f . 12-15% for Method
I I . ; .. . . .
. l . i t i  Radioactive synthesis of 4 - [^C] e thy nyl biphenyl.
Two batches o f 4 - [1If CJethynylbiphenyl were produced, one by each of 
the methods described. In each case i t  was found useful to perform a 
'co ld 1 synthesis alongside but one step ahead o f the radioactive synthesis 
using exactly the same quantities of m aterial.
In both cases I - [ 11+ C]-acetyl chloride was diluted with re d is tille d  
'cold' acetyl chloride and incorporated into the reaction as described 
previously.
The f i r s t  batch of I 1IfC]-ethynylbiphenyl was synthesized using 1.0  
mmol 1 — CJacetyl chloride (equivalent to 2.5 mCi), and Method I .  The 
second batch was made using Method I I  and 2.0 mmol 1 - [14C]-acetyl chloride 
(equivalent to 5.0 mCi).
The f i r s t  batch produced from 1.54 g of. 4-ethynylbiphenyl weighed 
220 mg (14% y ie ld ) and had a specific ac tiv ity  of 0.175 mCi/mmol.
The second batch (again from 1154 g of biphenyl weighed 310 mg 
(20% y ie ld ) , and had a specific a c tiv ity  of 0.327 mCi/mmol.
In both cases radiochemical purity was checked by chromatography • 
combined with radioautography and radioscanning. Chemical purity was
was checked by mixed melting point determination with pure 4-ethynyl­
biphenyl . Ihfcra-red spectra and mass spectra were also obtained and compared 
with authentic 4-ethynylbiphenyl (see Appendix).
SYNTHESIS OF 4 ,-HYDR0XY-4-BIPHENYLYLAC£TIC ACID
For the purpose of reverse isotope d ilu tion  and metabolite 
id en tifica tion  4 ‘ -hydroxy-4-biphenylyIacetic acid was synthesised. The 
reaction scheme was as follows:
Dimethyl
sulphate *  H^gO
4-Hyaroxybi phenyl 4-Methoxybi phenyl
Acetyl
chloride
v
// \> h2co.oh *- Morpjioline CH
Sulphur 3
CWlllgerodt reaction)
// / -CGCH,
4' -Methoxy-4-biphenylyl - 
acetic acid 4 1Methoxy-4-a ce ty1b i ph eny1
HBr
Acetic acid
CH2C00H
4' -Hydroxy-4-biphenylylacetic acid
■ -  47 -  /:■
\  . . .
All chemicals used were standard laboratory reagents of Analar grade. 
Acetyl chloride was purified by d is t illa t io n  and 4-hydroxybiphenyl by 
recrys ta lliza tio n  from ethanol.
The synthesis of 4 ' -methoxy-4-acetylbiphenyl was a modification of 
the method o f Gray e t  a l . ( 1955) and the further synthesis to 4 ‘ -hydroxy- 
4-biphenylylacetic a c id . was performed using the method o f Line!1 and 
Smith (1959).
4-Hydroxybiphenyl (42.5g9 0.25 mol) was dissolved in  hot sodium 
hydroxide (2M, 700 ml) in a one l i t r e ,  one-necked flask heated over a 
steam bath. When fu lly  dissolved the solution was cooled to 50°C and 
dimethyl sulphate (63g9 0.5 mol) added w hilst the temperature was 
maintained a t 50-60°C (o il-bath ) and s tirred  using a magnetic s t ir re r  
(fume-cupboard). The temperature was then raised to 70°C fo r 45 min 
a fte r which the reaction was cooled and the white prec ip itate  f ilte re d  
at the pump. A second, smaller y ie ld  of 4-methoxybiphenyl was obtained by 
treating the f i l t r a te  a second time with dimethyl sulphate (20 m l).
The crude 4-methoxybiphenyl was recrystallised from ethanol to give 
white plates m.p. 83°C. Yield 48.5 g (94%).
4-Methoxybiphenyl (24g9 0.13 mo!)was dissolved in dichloromethane 
(160 ml) in a 500 ml9 two-necked9 round bottomed flask and the solution  
cooled to 0-2°C. Freshly sublimed anhydrous aluminium trich lo rid e  
(2 1 .Og9 0.15 mol) was added carefully with s tirr in g  (magnetic s t ir re r )  
and acetyl chloride (13.4g, 0.15 mol) added over 5-10 min using a dropping 
funnel. The temperature was gradually raised to 35°C and when the 
vigorous reaction was over the mixture was refluxed (o il-b a th 9 60-70°C) 
for 2h. Evolved HC1 gas was passed d irec tly  to a fume-cupboard sink
with running water. After 2h the solvent v/as removed and the dark red 
residue hydrolysed by addition of ice-cold hydrochloric acid (5M9 80 m l).
The residue thus obtained was filte re d  at the pump and dried. Tritu ration  
with ether (2 x 80 ml) removed the isomeric 3-ketone produced as an 
impurity. The 4'-methoxy-4-acetylbiphenyl was decolourised by treatment 
with activated charcoal (20 g ). Following recrysta llisation  from 
isopropyl alcohol pale-yellow flakes were obtained, m.p. 253° ( l i t .  253- 
256°C) 29.5g (70%).
4 ‘ -Methoxy-4-acetylbiphenyl (10g9 0.04 mol) was dissolved in morpholine 
(30 ml) and powdered sulphur (5.7 g) was added with s tirr in g  (magnetic 
s t i r r e r ) . The reaction mixture was stirred  a t reflux (o il-b a th ) for 
5h a fte r which time the solution was poured into sodium hydroxide 
solution (13%, 150 ml) and refluxed fo r a further 4h, then cooled and 
f i lte re d  at the pump. The residue was extracted with boiling water (4 x 
100 ml) and the combined f ilt ra te s  acid ified  with hydrochloric acid (4M).
The precipiate was filte re d  and dried in  vacuo at room temperature.
Crude y ie ld  8g (75% y ie ld ) m.p. 182° ( l i t .  188°C).
Crude 4'methoxy-4-biphenylylacetic acid (8g) was refluxed in a 500 ml , 
one-necked round bottomed flask with glacial acetic acid (100 ml) and 
hydrobrormic acid (48%, 13 ml) for 5h. The reaction mixture was concentrated 
by evaporation under reduced pressure and the residue d ilu ted  with cold 
water to give a crystalline mass which on recrysta llisation  from acetic  
acid gave white plates of 4 ' -hydroxy-4 -biphenylylacetic acid, m.p. 245°
( l i t .  243-244.5°C), y ie ld  6 .8g (89%).
The pure product was analysed by mass-spectroscopy and n.m.r. to 
confirm p-substitution (see Appendix). FoundC 73.6%H-5.4% C14H1203 
requires C 73.7%. H 5.3%. The in fra-red  spectrum was also determined 
(see Appendix).
3. SYNTHESIS OF £-PHENYLMANDELIC ACID
£-Phenylmandelic acid (structure shown below) was synthesized fo r  
use as a standard in metabolic investigations.
H-COOH
£-Phenylmandelic acid
Diethylketomalonate was purchased from the Aldrich Chemical Company 
Other chemicals were standard laboratory reagents.
The method o f preparation was sim ilar to that outlined by Riebsomer 
e t  a7(1938) and can be summarised:
m )
\ — /  \ = /
COOC-H. 
I 2 5 
+ 0=0 SnCl
'2^5
Biphenyl
fcoOC;
Diethyl ketomalonate
-s>
cooc2h5
OH.SnCflv
cooc2h5
KOH
COOK
■COOH
HC1
£-Phenylmandel i c acid
Biphenyl (15.4g, 0.10 mol) was dissolved in dry chloroform (50 ml) 
in a 100 ml, one-necked, round bottomed flask at 4°C. Diethylketomalonate 
(3.5g, 0.02 mol) was added with s tirrin g  (magnetic s t ir re r )  and the 
solution maintained a t 0-6°C (ice-bath ). Anhydrous stannous chloride 
(3.5 ml) was added over a period of Ih and the reaction mixture kept at
4-10°C overnight W ith s tirr in g . The yellow-white precipitate was 
f ilte re d  a t the pump, washed with d ilu te hydrochloric acid (1M, 100 m l), 
water (2 x 100 m l), and the residue then dissolved in hot potassium 
hydroxide solution (20%, 50 ml) and heated over a steam bath for 2.5h.
The solution was then ac id ified  with hydrochloric acid (5M) and' 
heated fo r a further 4h to eliminate C0£. The product was extracted 
with ether (3 x 100 ml) and the combined extracts concentrated to about 
100 ml, washed with water (3 x 100 ml) and dried over anhydrous sodium 
sulphate. The ether was removed by evaporation under reduced pressure and 
the crude, yellow £-phenylmandelic acid decoloured by boiling with 
activated charcoal in methanol. Removal o f methanol afforded a white 
residue which was recrystallised from 50% aqueous methanol to give a 
white sem i-crystalline product which was dried in  vacuo a t room temperature 
The pure p-phenylmandeiic acid had a m.p. o f 193°C ( l i t .  192°C), y ie ld  
68% ( l i t .  63%).
Infrared spectra, electron impact mass spectra, and proton magnetic 
resonance spectra were obtained (see Appendix).
SUMMARY '
i )  4 - [llfC]ethynylbiphenyl was synthesized by two methods to give 
products of specific ac tiv ity  0.175 mCi/mmol and 0.327 mCi/mmol (220 mg 
and 310 mg respectively).
i i )  4 ‘ -Hydroxy-4-biphenylylacetic acid and £-phenylmandelic acid 
were synthesized for use in iden tifica tion  o f metabolites and for i n  v i t r o  
studies.
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3.1 INTRODUCTION
Themetabol ism of 4-ethynylbiphenyl has previously been studied 
i n  v ivo  using unlabelled drug. L it t le  was discovered about the 
. biotransformation and elimination o f the compound or its  metabolites . 
(Allen and Hanbury L td ., Mare, H erts .), except that the parent drug was 
not excreted unchanged.
The work reported here was performed using 4-[1 **Cjethynylbiphenyl 
(synthesis described in Chapter 2) to fa c ilita te  the iso lation and 
id en tifica tion  o f metabolites.
3.2 MATERIALS AND METHODS - ANALYTICAL, SECTION 
i S c in tilla tio n  Counting
All s c in tilla tio n  counting was carried out- using an LKB 1210 
liqu id  s c in tilla tio n  counter. The s c in tilla tio n  flu id  used was a 
modification of that described by Mood e t  a t  (1975). This comprised 
-  toluene (2 v o l.) ,  Synperonic NXP (1 vo l.) containing 2,5-diphenyl-  
oxazole (0.55%, w/v ) .  Aqueous samples (0.5 ml) were added to 4.0  ml 
of the s c in tilla tio n  flu id  and counted in p lastic m ini-vials (Packard Ltd. 
Counting efficiency (usually 75-90%) was determined by internal standard­
ization with either [ llfC]-toluene or [ ltfC]-hexadecane.
. i i  Autoradiography and Radioscanning of Thin-layer Chromatograms
Routine scanning o f th in -layer chromatography plates (TLC plates) 
was performed using a Camlab TLC plate scanner (Camlab Laboratories 
L td ., Cambridge). Autoradiography was used for more sensitive location  
of radioactive zones.
Autoradiographs were prepared using specially designed cassettes
that enabled TLC plates to be held firm ly in contact with sheets o f 
X-ray film  (Kodak Medical Blue Brand,BB54, 18 x 24 cm). The cassettes 
were routinely stored in black p lastic sacks, and for long exposure 
times (greater than 2 weeks) stored at -10°C to reduce background 
darkening. •
c o
Exposure times were 24 hr for zones containing 1 x 10 d.p.m./cm
3 2and three to eight weeks for those containing 1 x 10 d.p.m./cm .
Autoradiographs were developed using Kodak Universal Developer 
for 4 min, followed by a 30 sec. wash in 2% acetic acid solution, and 
fix ing  for 4 min in Kodafix (diluted 1:3 with w ater). A fin a l 20 min 
wash in running water was performed and the films hung up to dry a t 
room temperature.
3 .2 . i i i CHROMATOGRAPHY
a) Thin-layer .chromatography
Thin-layer chromatography (TLC) was carried out using 0.25 mm 
layer s ilic a  gel G .F ^ ^  plates (Schleicher and Schdll L td ., d istributed  
by Anderman h Co., L td ., London) and preparative-layer chromatography 
(PLC) on 2.0 mm layer s ilic a  gel 60 ^ 5 4  plates (E. Merck, Darmstadt, 
Germany). Solvents used were standard laboratory reagents of Analar 
grade.
The following solvent systems were used routinely:
A Toluene (90)/methanol (10)/ethyl acetate (17)/acetic  acid (3)
B Chloroform (50)/methanol (50)
C n-Propanol (70)/ammonia (30)
D n-Butanol (50)/water (25)/acetic  acid (11)
E Toluene (90)/methanol (10)/ethylacetate (17)/ammonia (3)
F Petroleum ether 60-80°C b.p. (95)/toluene (5 ).
These solvent systems are la te r  referred to as solvent system 
A, B, C, etc.
Spray reagents were-used to locate certain metabolites.
B rie f details are given below:
G lucosiduronates : Chromatograms were sprayed with 1% w/v  naphthores-
orcinol in acetone, to which 10% phosphoric acid had been added (4:1) 
immediately before use. The chromatogram was heated to 140°C (see 
Bridges e t a l ,  1965). '
G lycine con jugates: Chromatograms were sprayed with p-dimethylamino-
benzaldehyde (5%) in acetic anhydride mixed with dry acetone (1 :4 ),  
allowed to dry, and heated at 130°C for 2-5 min. Glycine conjugates 
usually give orange-red colours (Smith e t  a l 9 1969; El Masri e t aZ-, 1956).
General amino- a c id  con jugates: Chromatograms were sprayed f i r s t  with 
sulphuric acid and then ninhydrin. The method of Rydon and Smith 
(1952) was also used. Chromatograms.were exposed to chlorine atmosphere, 
placed in a current of warm a ir  for 20 min, and then sprayed with 1% 
starch -  1% potassium iodide solution. Blue-black spots were produced,
M ercap turic  a c id s : The method o f Knight and Young (1958) was used.
Chromatograms were sprayed with 0.1 M ^C^Oy -  acetic acid (1:1) 
followed by 0.1M aqueous AgNOg. A positive reaction is the appearance 
of orange spots on a brown background.
Cavboxylic a c id s : These were detected by spraying with bromocresol
green (0.04%) in ethanol (Lugg and Overall, 1948).
b) Ion-exchange chromatography
For desalting and partial decolourization of urine, faeces, a n d b ile
prior to TLC, XAD-2 resin was used (B ritish  Drug Houses Ltd, Poole, 
Dorset). Acidified aqueous samples were run on to columns of XAD-2
resin (bed volume approximately equal to sample volume). The column
was then washed with water to remove unwanted material and eluted 
with methanol. This procedure produced methanol elutes containing - 
> 90% of the radioactivity applied to the column.
The methanol eluates were sometimes further decolourised with 
activated charcoal before being concentrated and applied to TLC or 
PLC plates.
c) Gas-liquid chromatography
Gas-liquid chromatography (GLC) o f ra t urinary metabolites was 
performed using a Pye GCV with a 1 .5M column (4 mm internal diameter, 
silanized glass) containing 3% 0V1Oli 100-200 mesh Chromasorbs Q.
Carrier gas was nitrogen (32 ml/min) and detection was by flame-
ionisation (hydrogen 18 psi, a ir  5 ps i).
Temperatures used were:
In jector 300°C
Oven 180°C
Detector 310°C
An Autolab System I integrator was used combined with a Philips chart 
recorder (10 mv input).
Method
Radioactive 24 hr rat urine (40 mg 4 - [ llfC]ethynyl biphenyl/kg dose)
was treated with XAD-2 resin as described e a rlie r  and the methanolic
eluate concentrated and chromatographed by TLC in solvent system A.
The radioactive band corresponding-to. the major metabolite was scraped
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from the plate, eluted v/ith methanol, and chromatographed in solvent 
system B. The radioactive band (R^ 0.8} thus obtained was scraped 
and eluted as before and the eluate evaporated to dryness. The residue 
was dissolved in ethyl acetate (100 yV) and portions of this taken for 
d eriv itiza tio n  with diazomethane. The deriv tized residue was dissolved 
in ethyl acetate and a 4 pi sample taken for s c in tilla tio n  counting to 
estimate the weight of metabolite present. A portion o f the diazomethane 
treated metabolite was further treated with 0 ,N -b is -(tr im e th y ls ily l-)-  
trifluoroacetamide (BTSFA) to derivdtize hydroxyl groups not methylated 
by the diazomethane. Three samples were therefore chromatographed; 
free metabolite, diazomethane treated, and diazomethane/BTSFA treated . 
Sim ilarly treated standards of 4-biphenyl acetic acid and 4-biphenylyl-  
carboxvlic acid were also run. The diazomethane/BTSFA treated samples 
were investigated by mas-s-spectroscopy.
3 .2 .iv  Mass Spectroscopy
Electron impact mass-spectra were recorded on an A .E .I. MS12 mass- 
spectrometer equipped with a temperature programming fa c i l i t y .  Spectra 
was obtained by d irect insertion of samples at an accelerating voltage 
of 8 kV and ionising voltage o f 70 eV.
Samples were prepared for analysis by purification  using th in -layer  
chromatography, metabolites being located by quenching of uv lig h t (254nm) 
and/or detection of radioactivity by scanning or autoradiography. Zones 
of pure metabolite were obtained by chromatography in two solvent systems. 
The metabolites were then scraped from the TLC plates and eluted from 
the s ilic a  gel with meijjanol (AnalaR grade) in a cap illary  column as 
described by Rix e t a l  (1969). The eluates were run d irec tly  into small, 
methanol-washed, melting-point tubes, and evaporated to dryness using a 
stream of nitrogen from a fine ly  drawn cap illa ry . These tubes containing.
the dry samples were heat sealed and la te r  used as sample probes for 
d irect insertion mass-spectrometry.
Mass spectra o f a ll metabolites and standards are reproduced in 
the Appendix.
3.2.V Proton Magnetic.Resonance Spectroscopy ( P.M.R.)
Proton magnetic resonance spectra was recorded using a 90 MH^
Bruker WH-90 Fourier transform spectrometer operating at
ambient temperature. Tetramethylsilane (TMS) was used as the internal 
standard and chemical shifts (S) are expressed in p.p.m. downfield from
u
th is . Deuteromethanol or d^tero-acetone were used as solvents.
The p.m.r. spectra o f the major metabolite of 4-ethynylbiphenyl in 
ra t was obtained using a sample (8 mg) produced by extraction and 
purifica tion  from the urine of 10 rats dosed with ^^[^Cjethynylbiphenyl 
{40 mg/kg). Spectra o f authentic 4-hydroxy-4-biphenylacetic acid and 
jp-phenylmandelic acid were obtained for comparison. All spectra are 
presented in the Appendix.
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3.3 MATERIALS AND METHODS.-: EXPERIMENTAL SECTION
,i  Excretion Pattern o f \ l h C] in Rat and Rabbit Following Oral 
Administration of .4 -L^CTEthynyl biphenyl.
a) Animals
Male Wistar Albino rats (200 _+ 5g) were used in a ll experiments 
and were obtained from the Departmental Rodent Breeding Unito Male 
and female Dutch' rabbits (2.5 kg) were purchased from local dealers.
b) Materials
4 - ( llfC].£thynylbiphenyl (0.175 mCi/mmol) was that synthesized by 
Method I as described in Chapter 2. Rats were housed in glass metabolism 
cages (Metabowls, Jencons S c ien tific  Ltd.) that enabled separate 
collection o f urine, faeces, and expired a i r . j  Metal metabolism cages 
designed for separate collection of urine and faeces but not expired a ir  
were used for the rabbits.
c) Methods
Rat. Six male rats were dosed in tragastrica lly  by oral intubation 
with 4 - [f^CJethynylbiphenyl (40 mg/kg) dissolved in corn o il (0 o5 m l).
A single dose was administered, containing 5 yCi o f rad io ac tiv ity , and the 
urine and faeces collected at 6h, 24h and then daily for 7 days. The 
expired a ir  of two rats was passed through two Dreschel bottles containing 
ethanol amine (15%) in 2-ethoxyethanol and one containing toluene* A ir , 
dried over s ilic a  gel columns was pumped through the Metabowls and traps 
at about 200 ml/min.
Urine samples were made up to 100 ml with washings from the cage and 
0„5 ml aliquots counted in duplicate in 4.0 ml s c in tilla tio n  flu id  
(described e a r lie r ) . The remainder of the urine was stored a t -17°C.
Faeces were collected daily and frozen. Samples were homogenised in
water and made up to exactly 100 ml (approximately 1:10 d ilu tio n  w/ v ) . 
Portions o fth e  homgenate (0.5 ml) v/ere digested at room temperature 
with hyamine hydroxide (3 .0  m l). A fter 24h the digests were p a rt ia lly  
decolourized by addition of H^ O^  (0.25 ml, 100 v o l.) being allowed 
to stand at room temperature for several hours. F ina lly , hydrochloric 
acid (conc. 0.25 ml) was added and the mixture le f t  overnight. Samples 
of the digests (200 p i) were counted in tr ip lic a te  in 4 .0  ml s c in tilla tio n  
flu id  plus 0.3 ml water. Counting efficiencies of about 75% were 
obtained. ' '
Rabbit: Male and female rabbits (Dutch, 2-2.5 kg) were given a single 
dose of 4 - [ llfC]ethynylbiphenyl (40 mg/kg in 2*0 ml corn o i l ,  equivalent 
to 5 yCi) by oral intubation.
Urine and faeces were collected for 7 days. S c in tilla tio n  counting 
was carried out as described for the ra t.
3 .3 . i t  Tissue Distribution Studies,
The tissue distribution of [1IfC] in the ra t following the administration 
of single and repeated oral dose(s) of 4- [1IfC]*ethynylbiphenyl (40 mg/kg) 
was studied.
a) Materials
4 - [ 14C]'Ethynylbiphenyl (0.327 mCi/mmol) prepared by Method I I  
(Chapter 2) was used. Male and female Wistar Albino rats (200 + 5 g) 
were starved overnight before dosing and for four hours afterwards but 
were then allowed free access to food and water,
b) Methods
Rats were dosed intragastrically by oral intubation with a single 
dose of 4 - [ 1IfC]-ethynylbiphenyl in corn oil (0.2 ml, 40 mg/kg= 6 yCi)*
Three or four male rats were k illed  by exsanguination under lig h t : 
ether anaesthesia (cardiac puncture) at each of the following time 
points: T h ,2 h ,4 h , 6h, lOh, 16h and 24h. Three female rats were 
k illed  at 1 Oh and three at 24h.
Blood samples were heparinized and the plasma stored at -40°C.
The following tissues were removed and stored at -40°C: brain, spleen, 
kidney, l iv e r , muscle (hind limb), heart, lung, epididymal fa t ,  dorsal 
fa t ,  testes (ovaries), seminal vesicles, adrenals, stomach, small 
in testine and large in testir.e .
Tissue samples were prepared for s c in tilla tio n  counting as follows.
Brain, l iv e r ,  kidney and testes were separately homogenised in Z 
volumes of water (Ig  tissue + 2 ml water) . Portions of the homogenate 
(equivalent to 100 mg tissue) were solubilised in 1.0 ml Soluene-350 
(Packard) so lub iliser overnight at 60°C.
Stomach, small in testine, and large intestine were separately 
homogenised (Polytron homogeniser, Northern Media Ltd.) and made up 
to 50 ml with water. Aliquots of the homogenates (0.5 ml) were 
solubilized with Soluene-350 as above.
For other tissues, about 100 mg (50 mg fo r spleen) was accurately 
weighed into s c in tilla tio n  v ia ls . Solubilization was again with 
Soluene-^350 fo r 24h-48h.
When cool, 12 ml s c in tilla tio n  flu id  and 1.5 ml water were added 
to the digests to produce a clear mixture for s c in tilla tio n  counting. 
Counting efficiencies ranged from 20% (adipose tissue, spleen) to 70% 
(bra in , muscle).
Samples o f tissues were also homogenised in water and extracted 
with ethyl acetate at neutral pH and at pH 4 .0 . The concentrated
extracts were subjected to TLC to identify and localize metabolites.
c) Repeated daily dose
The tissue distribution of [1ItC] was determined in two rats that 
received daily doses of [1 **C]-ethynylbiphenyl (40 mg/kg) for 4 
consecutive days* The rats were k ille d b y  exsanguination under 
anaesthesia and the tissues examined as described above.
3 .3 . i i i  B ile, Duct and Ureter Cannulation Studies -  General Methods
a) Materials
Male Wistar Albino rats (250 + 10 g) were used. 4 - [ llfC]£thynyl- 
biphenyl was that prepared by Methods I and I I  (Chapter 2 ) . The 
chemical and radiochemical purity was checked by th in -layer chromatography, 
radio-scanning and autoradiography.
The polythene tubing used for cannulations was supplied by Portex 
Ltd ., Hythe, Kent.
The anaesthetic used was Nembutal (Abbott Laboratories L td ., 
Queensborough, Kent) which contained 60 mg/ml pentobarbitone.
b) Surgical procedures
' B ile -d u c t ca nnu la tions ; Anaesthesia was induced by a single in tra -  
peritoneal in jection of Nembutal (0.35 ml, equivalent to 21 mg pento­
barbitone). The animal was placed on its  back on a cork t i l e  and its  
limbs Tightly tensioned with rubber bands pinned to the t i l e .
A mid^line incision was made, extending from the g en ita lia  to the 
xiphisternum. The viscera were carefully displaced from the abdominal 
cavity and supported at the animals le f t  side on absorbent cotton wool 
previously soaked in warm saline solution (0.9% w/v ) .  To prevent
dehydration the viscera were covered with another saline-soaked swab*
The abdominal w a lls  were held apart with artery forceps to 
provide good accessib ility to the b ile  duct which was exposed by 
supporting part of the liv e r  with a spatula held in a re to rt clamp.
With the common bile-duct exposed the adhering fa tty  deposits were 
carefu lly  scraped away to clear 2 .0 -3 .0  cm of the duct.
The duct was then ligated towards the duodenal end so that 
accumulating b ile  expanded i t  to fa c ilita te  cannulation. A second, 
loose, ligature was then positioned 0.5 cm below the bifurcation o f the 
common b ile-duct, ready to secure the cannula when in place.
A small incision was then made in the b ile  duct using iridectomy 
scissors, and a cannula (Portex p lastic tubing PP25) inserted to a length 
of 1.0-1.5  cm. The proximal, loose, ligature was then tightened to hold 
the cannula securely. The free end of the cannula was exteriorised  
through the abdominal wall via a needle (la te r  removed). The viscera 
were then repiaced.
When a continuous flow of b ile  was obtained the abdominal cavity  
and skin were separately sewn and clipped. The animals were then covered 
with a blanket of cotton wool and warmed with two 150 watt lamps over­
head.
' lire  te r  carm i lo t io n s : In experiments' involving both bile-duct and ureter
cannulations the ureters were cannulated f i r s t .  The animals were opened 
as described for the bile-duct cannulations and the ureters exposed.
These were easily identified  as small pu lsatile  vessels e ither side o f 
the dorsal m id-line. In some animals, however, layers of adipose tissue 
made location d if f ic u lt .
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Ureter cannulation was found to be best performed by isolating  
one ureter, cleaning i t ,  ligating i t ,  and leaving i t  to swell with 
accumulating urine. After the second ureter had been sim ilarly  
prepared the f i r s t  was ready for cannulation.
Small incisions were made with iridectomy scissors and the cannulae 
(Portex tubing PP10) carefully inserted and ligated in place.
I f  both ureter cannulae flowed sa tis fac to rily  the bile-duct was 
cannulated as described above.
Anaesthesia was maintained throughout the experiments with Nembutal 
(0.05-0.15 ml9 equivalent to 3-9 mg pentobarbitone)0.
3 .3 . iv B ilia ry  Excretion of [l l fG] After Administration o f an Intraperitoneal 
f i,.p .)  Dose o f 4-p^Cj-Ethy.nvlbiphenyl or \ l h Cl-Biphenyl
Bile-duct cannulations were performed on twelve male Wistar Albino 
rats (250 + 10g) o Six were dosed intraperitoneally with 4 - [ llfC] ethynyl- 
biphenyl and six with £1IfC]-biphenyl c The doses comprised 40 yg 4 - [ llfC]- 
ethynylbiphenyl (_. = 100,000 d.p*m.) or 40 yg [1IfC]-bipheny1 (  = 100,000 d.pom.) 
dissolved in 0*75 ml saline containing 10% propylene glycol.
Control samples of b ile  were collected for 30 min prior to dosing*
These, and a ll subsequent samples v/ere collected in small, pre-weighed, 
plastic  tubes equipped with tig h t f it t in g  caps suitable for storage.
After dosing, the accumulated B ile was collected a t 30 min intervals  
for a total o f 7-10ho After determination of rad ioactiv ity  a ll samples 
were stored at -10°C.
For s c in tilla tio n  counting 50 yl samples were counted in duplicate 
in plastic m ini-vials containing 4 ml s c in tilla tio n  flu id  and 0*5 ml water.
This mixture produced clear samples for counting and effic iencies o f 
about 85% were obtained.
3 .3 .v  E ffect o f Dose Level,on B ilia ry  Excretion of [ llfC].,
Three rats were investigated at each o f the following dose levels:
0.16 mg/kg, 5 mg/kg, 10 mg/kg,2 0  mg/kg, 40 mg/kg, 80 mg/kg, and 100 mg/kg* 
Doses comprised ^-[^Cjethynylbiphenyl (1 x 10 d.p.m*) diluted with 
unlabelled drug, dissolved in corn o il (0 .5 ml)* These doses were 
administered by injection into the duodenum prior to the animals being 
sutured. B ile samples v/ere collected as before.
3 .3 *v i Comparison o f Excretion in B ile and Urine Following an In tra -
duodenal Dose of 4-[T4C] Ethynylbiphenyl *
Six male Wistar Albino rats (250 + lOg) were cannulated as previously 
described and dosed intraduodenally with 4 - [^C ] ethynyl biphenyl (40 mg/kg) 
in corn o il (0.25 The excretion of [ 1IfC] in both b ile  and urine was
fo l1 owed over 6-1 Oh.
3ft3 .v i j  Investigation of Enterohepatjc Circulation in the Rat
Bile was collected from two rats which had previously been dosed • 
intraduodenally with 4 - [ 14C] ethynylbiphenyl (40 mg/kg). This b ile  was 
administered intraduodenally to other ra ts . Appearance o f rad ioactiv ity  
in the b ile  of these rats was taken as proof o f enterohepatic c ircu la tion .
Normal, an tib io tic  treated, and saccharo-lactone treated rats were 
used. The antib io tic  treatment consisted of twice da ily  oral doses o f 
te tracyclin  (40 mg) and neomycin (10 mg) for a period of 5 days, the las t 
dose being 1 hour before the experiment. Other rats received 1 ,4 .-saccharo- 
lactone (250 mg, aqueous solution) intraduodenally 30 minutes before the 
experiment.
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B ile samples (cumulative) were collected every 30 minutes into  
pre-weighed vials and 100 yl samples taken for s c in tilla tio n  counting.
3 .3 .v i i i  Isolation and Identifica tion  of Metabolites
Samples of b ile , urine and faeces were used for isolation and 
id en tifica tion  of metabolites.
Sulphatase enzyme preparations and peptidase (purified  from hog 
in testinal mucosa) were obtained from Sigma Chemical Co., London.
Ketodase (purified  [3-glucuronidase dissolved in acetate buffer a t 
pH 5.0) was purchased from Warner and Co., L td ., Eastleigh, Hampshire.
a) Faeces
Rat and rabbit faeces were freeze-dried, ground with s ilica -g e l 
(70-230 mesh, Merck, Darmstadt),and the powdered mixture eluted with 
methanol and methanol-ethyl acetate (50-50) on a glass column. The 
eluate was concentrated under reduced pressure, re-dissolved in methanol, 
and decolourised by boiling with activated charcoal. The la t te r  procedure 
was shown not to remove any rad ioactiv ity . The resultant methanolic 
solution was concentrated by rotary evaporation under reduced pressure.
The residue was examined by th in-layer or. preparative-layer chromatography 
before and a fte r enzymic and acid hydrolysis.
Hydrolysis of glucuronides was achieved using Ketodase and sulphates 
were treated with one of several sulphatase preparations in acetate buffer 
pH 5.0. Incubations were at 37°C for 12-24h. Sulphatase preparations had 
1-4 saccharo-lactone (100 mM) added to in h ib it any B-glucuronidase-activity 
present as an impurity. Control incubations were performed using e ither  
phenolphthalein glucuronide or 1-naphthylsulphate to check enzyme a c tiv ity .
Acid hydrolysis was performed using HC1 (4.5 M) at 50°C fo r 6-12h.
Control incubations of samples with buffer (pH 5 .0 )were carried 
out to monitor any non-enzymic hydrolysis o f conjugates.
b) Urine
Untreated ra t and rabbit urine was examined by th in -layer and 
preparative-layer chromatography in solvent systems A, B, C and D*
In most cases the urine contained insuffic ien t rad ioactiv ity  for radio­
scanning and was desalted, decolourized and conc^fcrated by XAD-2 
treatment as described for faecal extracts. These concentrated extracts 
were chromatographed before and a fte r enzymic or acid hydrolysis.
Extraction of urine with ethyl acetate a t various pH values was 
carried out to determine the nature o f the metabolites present i .e .  free  
or conjugated, acidic or basic.
c) B ile
Generally b ile  samples contained insu ffic ien t rad ioactiv ity  for 
direct investigation by th in-layer chromatography and autoradiography. 
They were therefore pooled, cleaned up on XAD-2 resin, and concentrated 
as previously described.
To examine b ilia ry  conjugates, 100 pi o f b ile  was incubated with 
one or other of the following; 200 pi ketodase solution (pH 5*0, 
equivalent to 1000 units ^-glucuronidase), 200 pi acetate buffer 
containing 500 units of sulphatase enzyme, 200 pi HC1 (4 .5  M), or 200 pi 
acetate buffer (pH 5 .0 }. Incubation was either overnight or for 24h, 
a fte r which time the incubates were freeze-dried and the residues taken 
up in 100 pi methanol-ethyl acetate (70:30) o f which 50 pi was examined 
by tH in-layer chromatography. Radioactive metabolites were located by 
autoradiography.
-  6 /  -
Concentrated b ile  extracts were hydrolysed in a sim ilar fashion, 
the dry residue equivalent to 1 ml b ile  being incubated with either  
2 ml buffer + enzyme, 2 ml buffer, or 2 ml HC1 (4 .5  M). The incubates 
(12-24h at 37°C) were extracted with ethyl acetate and the extracts 
concentrated and chromatographed on th in -layer plates. The aqueous ;
residue was freeze-dried, taken up in methanol and s im ilarly  chromatographed,,
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3 .4 . RESULTS
3 e4 . i  Excretion Patterns in Rat and Rabbit
The excretion patterns of [ 1IfC] in ra t and rabbit a fte r  the 
administration of a single oral dose o f 4 - [^C]-ethynyl biphenyl (40 mg/kg) 
are shown in Table 3 .1 .
The ra t excreted 65-75% of the administered [ lJtC] in the urine 
and 20-30% in the faeces over a period o f six days, with detectable 
amounts (up to 1% o f the dose) s t i l l  appearing on days fiv e  and s ix Q At 
24h 50-55% of the administered radioactiv ity  had been excreted (about 
43% in the urine and 9% in the faeces), and a t 48h greater than 70% had 
been eliminated. Faecal excretion was greater on the second day than 
the f i r s t ,  and from the th ird day was s lig h tly  greater than urinary t 
excretion of rad io activ ity0 No radioactivity was found in the expired 
a ir .
The rabbit disposed o f the drug more quickly and 70-75% appeared in 
the 24h urine and a further 15-20% by 48h. In contrast to the ra t , a 
to tal o f only 5-10% of the administered radioactiv ity  was excreted in 
the faeces (compared to 20-30%). There was negligible excretion of 
rad ioactiv ity  a fte r  72h in the rabbit, whereas the ra t excreted 5-10% 
between the th ird and sixth day.
.4 ci i  Tissue Distribution Studies (Rat)
The results o f the tissue distribution study are shown in Table 3 .2 , 
and the plasma clearance shown in Figure 3 J .  The drug was quickly and 
completely absorbed from the gastro-intestinal tra c t. Levels of [ llfC] 
in the stomach, small in testine, and large intestine are shown in Figure
3 .2 .'■■'.At Ih about 30% of the dose remained within the stomach but a t 4h
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Table 3.2 Tissue distribution of 4 - [ llfC]ethynylbiphenyl in ra t with time
^ \ T i me (H) 
Tissue^**'*'*,,,. 1H 2H 4H 6H 1 OH 16H 24H
**
24H
Adipose 
(Dorsal)
66 97 167 206 124 67 79 68
Adipose
(Epidymal)
28 61 102 140 93 51 60 59
Li ver 46 43 53 56 28 15 16 17
Kidney 28 .2 6 31 35 39 20 13 14
Lung 26 27 21.0 25 25 9 6 5 .0
Spleen 10 8 8 10.0 9 2 - 1 .0
Brai n 11 11 10 7 4 1 - 0.5
Muscle 7 7 8 8 8.5 1 1 1 .5
Testes 7 9 9 12 10 3 2 2.0
Seminal
Vesicles
2 1.5 2 2.5 2 1 > 0.5
Adrenal 2 3 2 3 1 0.5 - 0.5
Heart 16 14 16 18 16 4 3 1 .5
Stomach* 2610 1411 429. 281 90 119 2 9 .0
Small In testine* 794 404 340 760 740 238 145 157
Large In testine* 68 74 348 542 549 367 171 343
The tissue distribution of [ lhC] in the ra t following a single oral dose 
o f 4- [i^c]ethynylbiphenyl (40 mg/kg) was determined at several time intervals  
a fte r dosing and are the mean values for three animals (see Appendix for 
detailed results including female ra ts ).
*  yg .Drug equiv./organ.
* *  These figures are those from animals (two) dosed daily (40 mg/kg) for 
four days.
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Figure 3 .1 . Distribution of rad ioactiv ity  in plasma (ra ts )
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Following a single oral dose o f 4 -£1IfC]ethynylbiphenyl 
(40 mg/kg) levels of rad ioactiv ity  in ra t plasma were 
determined at several time points. The results plotted  
are the mean + s.e.m. of four animals.
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Distribution of rad ioactiv ity  in  gastrointestinal 
tra c t (ra t) wi th 'tim e •
Figure 3.2
0.8
0.4 \/
-A
Time a fte r  dosing (h)
Following a single oral dose of [ ilfC]ethynylbiphenyl the ra d io a c tiv ity
contents o f stomach, small in testine , and large intesdHne were determined. 
Results plotted are the means o f three animals.
o— © Stomach 
* —^  Small in testine  
®— 0 Large in testine
the level was less than 5%0 The levels o f radioactiv ity  in the small 
intestine showed an in it ia l  maximum at Ih , followed by a rapid decline 
as the drug was absorbed, but by 6h the levels were rising and another 
peak was observed between 6-1 Oh.
The tissue that exhibited the greatest concentration of radio­
a c tiv ity  was the adipose tissue, both dorsal and epididymal. The 
levels of rad ioactiv ity  found in these tissues a t th e ir  peak (6-1 Oh) 
corresponded to 150-200 pg equivalent of parent drug/g tissue. This 
compares with a maximum o f 30-40 pg/g tissue found in the liv e r  and 
kidneysc At 6h, a t least 20% of the administered rad ioactiv ity  was 
localized in the adipose tissue, assuming that a 5-7% of the body-weight
of a'200g ra t to be adipose tissue (Reed, e t  a l ,  1930; Schemmel,
Micklesen and Mostosky, 1970). Absorption of rad ioactiv ity  into 
adipose tissue was rapid (Figure 3 .3 ), maximum concentrations being 
between 6-8hc There was subsequently a steady loss of rad ioactiv ity  from 
the adipose tissue until at 24h a level o f 50 pg drug equivalent/g tissue 
was observed (equivalent to about 9% of the dose)c Rats given repeated 
daily doses for 4 days did not have s ign ifican tly  higher concentrations 
of radioactivity in th e ir adipose tissue (Table 3 .2 ) .
There was a sex difference in the concentrations of rad ioactiv ity  
both in dorsal ( ‘ brown1) adipose tissue and genital adipose tissue at 
both time points studied (p < 0o10 at 1 Oh, p < 0.01 a t 24h)0 Female rats 
had a greater concentration of radioactivity per g of fa t  especially a t 
24h (Table 3C1 )0 The only compound detectable in the adipose tissue was
the parent drug, 4 - [ llfC]ethynylbiphenyl.
The levels o f radioactivity in the plasma rose quickly up to 2h and 
then more slowly until maximum levels were seen a t 1 Oh, 140 pg drug
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Figure 3 .3 . Distribution or raa ioaccm ty in auipuse ubbut: wi ui  umic w aw
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Following a single oral dose of [ llfc]-4-ethynylbiphenyl (40mg/kg) 
rad io ac tiv ity  was determined in dorsal adipose tissue (so lid  c irc le s )  
and epididymal fa t  pads (solid squares). Results are the mean ± s.e-.m. 
fo r three animals.
equivalent/ml plasms [FtguTe 3 .1 }. After 16h levels had fa llen  to 30 g 
drug equivalent/ml plasma.
3 .4 . i i i
Plasma samples were extracted with ethyl acetate and investigated 
by TLC. Three metabolites were identified  as well as the parent drug. 
These were 4-biphenylylacetic acid, 4 ‘ -hydroxy“4-biphenylylacetic acid, 
and £-phenyIacetophenone, metabolites I ,  I I  and I I I  below:
4-biphenylylacetic acid
4,-hydroxy-4-bi phenylyl aceti c
acid
£-phenylacetophenone
All three metabolites were identified by co-chromatography with 
authentic materials, mass spectroscopy, and reverse isotope d ilu tio n  for 
I  and I I .
The amounts of these metabolites in the plasma are shown in Figure
3.4 as percentages o f total rad ioactiv ity . There were no metabolites 
found that contained an in tact ethynyl group.
B ilia ry  Excretion
a] B ilia ry  excretion of [llfCj a fter a single intraperitoneal dose o f 
4 - [ 1¥C}ethyhylbiphenyl or [lH C]-biphenyl
The results o f this experiment are shown in Figure 3 .5 . B ilia ry  
excretion was more rapid in animals dosed with [ llfC]-biphenyl than in 
those dosed with 4 CJ-ethynyl biphenyl. In the former about 15% o f the
0-0 -Cf^COOH
IT
I I I O '
CH„C00H
-CH.
- j  a
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Figure 3.4 Distribution of Radioactivity in Plasma (Rat)
100-
CC.
104 82 6
Time a fte r dosing (Ti)
E thy nyl biphenyl and its  metabolites in ra t plas were 
quantitative ly determined at 1, 2, 4, 6 and I Oh.
The results plotted are the mean + s.e.m. of three animals.
©— © 4-Ethynylbtphenyl 
o— a 4-Hydroxy-4-biphenyly1acetic acia 
A x  4-BiphenylyI acetic acid
o— o 4-Acetyibiphenyl
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Figure 3.5 . Bi1iary excretion in ra t
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4 - t14CjEthynylbiphenyl and Biphenyl (^*16 mg/kg) were dosed in traperitoneally  
and 4 - [ll*C]ethynylbiphenyl (0.16 mg/kg) intraduodenally to b ilia ry  
cannulated rats. Excretion of radioactivity was measured fo r a t least 
7 hours.
4 - [ ll+C]ethynylbiphenyl (intraduodenal)
0— a 4 - [ 1I*C]ethynylbiphenyl (in trap e rito n ea l) 
a— ▲ [ llfC]biphenyl (in traperitoneal)
dose was eliminated in 7h compared to 8.5% in the la t te r .  After an 
intraduodenal dose of ;4 -[^Cjethynyl biphenyl (0.16 mg/kg) there was 
a threefold increase in the rate of excretion of rad ioactiv ity  compared 
to intraperitoneal ly  dosed-rats.
b) Effects o f dose level on b ilia ry  excretion
The excretion of [14C] expressed as a percentage of the dose 
appearing in the pooled six hour b ile , at dose levels of 0.16, 5, 10,
40, 80 and 100 mg/kg, is shown in Figure 3 .6 .
Between 40 and 100 mg/kg the percentage of the dose excreted in 
in the b ile  over 7h remained constant (range 6.3-7.0%) w hilst 20, 10, 
and 0.16 mg/kg doses produced increased percentages. Up to 30% o f the 
dose was excreted in the b ile  at 0.16 mg/kg0
c) Excretion of [1£|Cj in b ile  and urine a fte r intraduodenal administration 
Of 4 - r 1**Cj ethyny1b i phe ny1 .>
The excretion rates of radioactivity in b ile  and urine a fte r  single 
intraduodenal doses of 4 - [ 1IfC]ethynylbiphenyl (0.16 mg/kg or 40 mg/kg) 
are shown in Figure 3.7,
At both dose levels excretion in the b ile  exceeded that in  the
urine, 25% of the dose compared to 6% at the lower dose, and 7% compared
to 6% at the higher dose ■ (6h a fte r dosing).
d) Investigation of entero-hepatic circulation in ra t
B ilia ry  excretion in rats dosed intraduodenally with b ile  from a 
ra t dosed with 4 - [lftC]ethynylbiphenyl (40 mg/kg) was examined fo r radio­
a c tiv ity . Excretion was also studied in rats treated with an tib io tics  and 
saccharo-lactone. The results are shown in Figure 3 .8 .
In untreated rats 26-28% of the adminstered rad ioactiv ity  appeared
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Figure 3 .6 . Effect o f dose level on b ilia ry  excretion in ra t
10040 50
Dose (mg/kg)
20 70 806010 30
Cumulative 6H b ilia ry  excretion of radioactivity was measured at 
several dose levels (0.16 mg/kg - 100 mg/kg).
All values represent the mean +s .e .m . for three animals.
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Figure 3.7. Excretion of radioactivity in b ile  and urine (ra t)
0.16 mg/kg25
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5
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Time a fte r dosing (H)
Rats were f it te d  with bile-duct and ureter cannulae and following a 
single oral dose of 4 - [J 4 C]ethynyl biphenyl (40 mg/kg or 0.16 mg/kg) 
the b ilia ry  and urinary excretion of radioactivity was investigated. 
The results plotted are the mean + s.e.m. for six animals.
a— a. Bile  
a— a Urine
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Figure 3 .8 . Demonstration of enterohepatic c ircu la tion  in ra t  
and its  Tnh'ibitioh~by ore treatment with saccharo^
lactone or antibiotics"
to
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o
Time a fte r  dosing (h)
Rats* normal or pretreated (250 mg saccharolactone intraduodenal, or
tetracycline 30 mg and neomycin 10 mg o ra l) were intraduodenally dosed
with radioactive b ile  and b ilia ry  excretion o f ra d io ac tiv ity  in the 
rec ip ien t rats monitored. Results are the mean values fo r two ra ts .
a— * Normal
©— © Saccharolactone treated  
o— o A ntib io tic  treated
in the b ile  within 6h, whilst in rats treated with antib iotics the 
levels fe ll  to 5% and in rats dosed with saccaro-lactone to 8-9%.
3 .4 d v  Isolation and Identification  of Metabolites
a) Urine
Rat; Urine from rats dosed with 4 - [ lifC]ethynylbiphenyl was 
repeatedly extracted with ethyl acetate at a range of. pH's from 5.0 
-  10.0. The following results were obtained:
pH % Extraction into 
ethyl acetate
10.0 A o
7.0 > 95%
5.0 ' > 98%
These results suggested that the metabolites of 4-ethynylbiphenyl 
were predominantly acidic and unlikely to be simple ring-hydroxylated 
derivatives.
Thin-layer chromatography of ra t urine in solvent system F 
confirmed that there was no unmetabolized 4-ethynylbiphenyl in the urine. 
When rechromatographed in the same solvent system this la t te r  radio­
ac tiv ity  migrated as a single band, R^  0 .4 , suggesting that the metabolite(s) 
was/were o rig in a lly  bound at the o rig in , possibly by proteinaceous m ateria l, 
or as conjugate(s) la te r hydrolysed. When chromatographed in solvent 
system B, over 90% of the urinary radioactiv ity  migrated as a single band,
0 .8 , as did the radioactivity from the band a t R^  0.4 in solvent system 
A. This confirmed the presence of a single major metabolite (approx. 90%) 
in ra t urine.
Autoradiographs of the solvent system A chromatograms showed fa in t
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bands o f radioactivity a t 0.48 and 0.37. Chromatography o f 
concentrated ethyl’.acetate extracts of urine showed the metabolite
i.
at R^  0.48 accounted for 0-5% of the urinary rad ioactiv ity  and co­
chromatographed with 4-biphenylylacetic acid. Mass-spectroscopy 
confirmed this iden tity .
When the major metabolite ( I ] and its  derivatives were examined 
by gas-liquid chromatography the following results were obtained:
Compound Retention time (min)
Untreated metabolite . 240
+ diazomethane 49
+ diazomethane 38
and BSFTA
The untreated metabolite had a retention time of 4h and produced a 
wide peak with extensive ta ilin g  suggestive o f an acidic structure. 
Derivatization with diazomethane produced a shorter retention time o f  
49 min. but there was s t i l l  a degree o f ta ilin g  indicating the presence 
o f an underiv;tized polar residue. The double, and probably fu lly  
deriy tized sample produced a narrower peak with no ta ilin g  and a 
retention time of 38 min. These results suggested that one o f the 
following structures was the major metabolite.
H-C00H (a) p-phenylmandelic acid 
OH
HpCOOH (b) 4 ,-hydroxy^4-biphenylyl
acetic acid
Investigation o f the sample by mass-spectroscopy revealed that the 
major metabolite v/as (b ). The carboxylic function had been es terified  
with diazomethane to the methyl ester and the phenolic tOH with BFSTA 
to the tri-m eth y ls ily l derivative.
Both (a) and (b) were then synthesized and the major urinary 
metabolite I positively identified  as 4 l-hydroxy-4-biphenylylacetic 
acid by reverse isotope d ilu tio n , co-chromatography, and electron 
impact mass spectra. The positive location of the phenolic group 
in the 4 ‘ -position was established by proton magnetic resonance (p .m .r). 
Details of a ll mass spectra and p.m.r. spectra are presented in the 
Appendix.
Babbit: When rabbit urine was extracted with ethyl acetate only 50% 
of the total radioactivity was found in the organic phase. This 
extractable radioactiv ity  when run in solvent systems A and B had 
values of 0.4 and 0.8 respectively, corresponding to the major rat 
metabolite, 4'-hydroxy-4-biphenylylacetic acid. Analysis by mass- 
spectroscopy confirmed this structure. Therefore 50% o f urinary radio­
a c tiv ity  (range 42%-61%) was present as unconjugated 4 '-hydroxy-4- 
biphenylylacetic acid.
When untreated rabbit urine was chromatographed in solvent system 
D (aqueous, polar system) several bands o f rad ioactiv ity  were located. 
Autoradiography showed five metabolites (Figure 3 .9 )* the major o f 
which corresponded to 4 I-0H-4-biphenylylacetic acid. This was confirmed 
by mass spectroscopy.
The other metabolites (accounting for 50% of the to ta l)  were not 
positively identified  but two ( I I I ,  IV, Fig. 3 .9) when investigated by 
mass-spectroscopy gave characteristic ions at m/e  194 and m/e  167, 
corresponding to the following structures:
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Figure 3.9 Radiochromatogram of a th in-layer chromatogram 
of rabbit urine
Solvent
front
Following a single oral dose of 4 - [ 14Cjethynylbiphenyl a 
sample of 24 hour urine was chromatographed (solvent system 
D) and a radiochromatogram prepared.
[The production of these structures is explained in the Appendix).
The structure [a) above, the biphenylketene, is a characteristic  
degradation product of amino acid conjugates o f biphenylylacetic acid 
[Sullivan, McMahon, Hoffman and Ridolfo, 1977). This suggested that 
metabolites I I  and I I I  were amino acid conjugates of 4-biphenylylacetic 
acid, although there were no appreciable parent ions in the mass spectra 
of these samples and no positive conclusions could be made.
Acid hydrolysis of urine (4M HC1, 70°C overnight) followed by shaking 
with ethylacetate resulted in greater than 99% extraction of rad ioactiv ity  
into the organic phase. Thin-layer chromatography o f this extract showed 
that about 90% (range 85-93%) of the rad ioactiv ity  was present as 4'-hydroxy- 
4-biphenylylacetic acid and about 6% as 4-biphenylylacetic acid. In addition 
there appeared to be a small amount of jo-phenylmandelic acid present (1-2%) 
as judged by co-chromatography with authentic m aterial. This was la te r  
positive ly  iden tified  by mass-spectroscopy. As was the case with ra t urine, 
autoradiography showed numerous minor metabolites to be present.
Spray reagents for mercapturic acid gave no positive results with 
rabbit urine or faecal extracts.
- 87 -
b) B jle (Rat)
Extraction of b ile  with organic solvents removed about 5% of total 
rad ioactiv ity  indicating that the metabolites present were conjugates.
The rad ioactiv ity  that was extracted was shown to be 4 '-hydroxy-biphenylyl- 
acetic acid with a trace of 4-biphenylylacetic acid.
Acid hydrolysis of b ile  followed by ethyl acetate extraction 
removed a ll o f  the radioactivity into the organic phase. When 
concentrated samples were chromatographed (Fig. 3.10) the ra d io a c tiv ity ' 
was shown to be 4'-hydroxy-4-biphenylylacetic acid (65-85%) and 4-biphenylyl­
acetic acid (15-30%). The re la tive  percentages of the two metabolites 
changed during the 7-10h experimental period. Increasing amounts o f 
4'-hydroxy-4-biphenylylacetic acid and reduced amounts of 4-biphenylyl­
acetic acid were found with time. The la tte r  metabolite was s t i l l  
present lOh a fte r  dosing when i t  accounted for only 8% of the rad io ac tiv ity .
Product analysis of b ile  hydrolysed with ^-glucuronidase, sulphatase 
and hydrochloric acid followed by ethyl acetate extraction and TLC gave 
the results shown in Figure 3.10. Both enzymes released free 4 ‘ -hydroxy- 
4- biphenylylacetic acid (R^ 0.4) in equal amounts. In addition they 
both released a metabolite with a low R^  value (R^ 0.1) not present in 
an acid hydrolysed sample. When scraped from the TLC plate and subjected 
to acid hydrolysis 4 ‘-hydroxy-4-biphenylylacetic acid was produced. The 
metabolite gave a very fa in t orange colour with £-dimethylaminobenzaldehyde 
spray suggesting an amino acid conjugate. Long term autoradiography of 
b ile  extracts showed the presence o f several trace metabolites which were 
not present in su ffic ien t amounts to be isolated. As in the urine extracts 
they were probably various ring hydroxylated metabolites.
Figure 3 .TO. Hydrolysis of b ilia ry  conjugates in ra t b ile
Solvent 
A fro n t
1 Rf  ° - 45
n  Rf  0 .4
m m m m xm x .■mmmmmrnfoiu  Rf o . i
J Origin
ACID SULPHATASE b-GLUCURONIDASE
HYDROLYSIS
Radioactive b ile  samples were hydrolysed with sulphatase (with 1 -4 , 
saccharolactone to in h ib it 3-glucuronidase impurity), 3-glucuronidase 
fketodase), or HC1 (4M). Aliquots o f ethyl acetate extracts were 
chromatographed (solvent system DJ,and an autoradiogram prepared. 
Organic extracts of control incubates (no acid or enzyme) removed 
very small amounts of radioactivity which remained at the o rig in .
I 4-Biphenylylacetic acid
I I  4'-Hydroxy-4-biphenylylacetic acid
I I I  Amino acid conjugate ? (see Text)
3 .5 DISCUSSION
I t  has been shown that 4-ethynylbiphenyl was extensively metabolised 
in both ra t and rabbit. Both aromatic ring hydroxylation and oxidation 
of the ethynvl group were observed. No metabolites containing an in tact 
ethynyl group were isolated from urine, faeces or b ile  of e ither species. 
The major excretory product was found to be 4 1-hydroxy-4~biphenylylacetic 
acid (80-90%) with 4-biphenylylacetic acid representing 2-10% of the 
to ta l. These compounds probably represent the active metabolites 
responsible for the i n  v ivo  effects observed with ethynylbiphenyl, both 
toxic and beneficia l.
Metabolism of 4-ethynylbiphenyl was very d iffe ren t to that of phenyl-  
acetylene (El Masry e t  a l . 1957, 1958), a closely related compound,which 
was shown to undergo very slow metabolism with no ring hydroxylation. 
Whereas 70% of ethynylbiphenyl was excreted in 24h by the rabbit the 
figure for phenyl acetylene was only 15%. In contrast to ethynylbiphenyl 
unchanged phenyl acetylene was excreted over a 3-day period. The presence 
of the second aromatic ring therefore has a profound influence on the 
susceptib ility  o f the acetylene group to undergo metaoolism. This might 
be because of altered b ioava ilab ility  of the compound to the drug 
metabolizing system, or because o f increased metabolism due to increased 
protein binding. Further aspects of the metabolic conversion of the 
acetylenic bond and its  possible toxicological implications are discussed 
in Chapter 4.
The a b ility  of the liv e r  to metabolise the ethynyl group of. 4-ethynyl 
biphenyl so extensively and quickly is intriguing in view o f the apparent 
s ta b ility  o f the group in other drugs. The results presented here 
suggest that a more detailed and modern investigation o f these other 
drugs might reveal previously unidentified metabolites resulting from 
sim ilar biotransformations.
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Tissue distribution studies in the ra t showed that 4-ethynylbiphenyl 
was quickly absorbed from the gastrointestinal tra c t and lik e  many highly 
lip id -so lub le  hydrocarbons quickly deposited in adipose tissues. This 
is a property well known, for example, in the case o f compounds lik e  
hexachlorobenzene and the thiobarbiturates (Parke, 1968). The persistence 
of such compounds within the adipose tissue depends largely on their  
chemical structure. Chemicals lik e  the chlorinated hydrocarbons which 
are metabolically stable can remain stored for very long periods o f time.
Such persistence is undesirable and is avoided by designing drugs that 
are quickly metabolized to a less lip o p h ilic  metabolite or by incorporating 
hydrophilic groups into the drug. In the case o f 4-ethynylbiphenyl rapid 
metabolism quickly produces hydrophilic, water soluble metabolites leading 
to a steady removal of the drug from the fa t depots. Repeated dosing of 
4-ethynylbiphenyl did not lead to increased deposition o f the drug.
The in it ia l  deposition of 4-ethynylbiphenyl in adipose tissue gives 
rise to a gradual release of the drug to the metabolizing systems of the 
liv e r  and other tissues. This can extend the excretion time of the orug 
and hence the exposure time of the tissues to i t  and its  metabolites.
The only other tissues with s ign ifican t levels of rad ioactiv ity  
were the liv e r , kidney and lung (Table 3 .1 ) , although those in the la t te r  
two tissues were only about h a lf that in  the l iv e r  (as yg equivalent drug/ 
g tissue ).
Peak levels of radioactivity in the liv e r  were reached 4-6h a fte r  
dosing, whereas in the plasma the peak levels occurred between 6-10h.
This probably reflects the binding of metabolites to plasma proteins, the 
influence of b ilia ry  excretion and enterohepatic c ircu lation . The combined 
effects o f these could give elevated blood levels o f metabolites a fte r  phase 
I metabolism in the liv e r . This is  discussed in more detail la te r . .
Although the major metabolite of ethynylbiphenyl was the same in  
ra t and rabb it, there was a marked difference in excretion patterns.
Whereas faecal excretion was sign ificant in the ra t (accounting fo r up 
to 30% of the dose) the rabbit eliminated nearly a ll its  metabolites 
in the urine with only 9% appearing in the faeces. The drug was also - 
eliminated faster from the rabbit, the same amount being excreted in 24h 
as a fte r 48h in the ra t (75% and 85% respectively). There were several 
possible reasons fo r this species difference.
One explanation might have been a difference in the rate of aromatic 
hydroxylation o f biphenylylacetic acid, a biotransformation necessary 
for elimination of the drug. £-Hydroxylation of biphenyl in both species, 
however, has been shown to be sim ilar (Creaven e t  oX. 1965), although 
the presence of a carboxylic acid group might affect th is .
Differences in b ioava ilab ility  of the drug could also explain the 
faster elimination shown in the rabbit. 4-Ethynylbiphenyl became rapidly  
and extensively localized in the adipose tissue o f the ra t. Tissue 
distribution was not studied in the rabbit but such loca liza tio n  would 
also be lik e ly  with such a lip o p h ilic  drug unless there was a marked f i r s t  
pass effec t due to extensive metabolism by in testinal m icroflora or the 
in testinal wall prior to absorption. Experiments with gut microflora 
(Chapter 4) did not support this possib ility  however, and although metabolism 
by the intestinal wall was not investigated this tissue is not generally 
responsible for extensive metabolism of drugs in  v iv o , despite its  a b il ity  
to exhib it almost a ll  types of biotransformation in  v i t r o  (Shirkey, 1977; 
Testa and Jenner, 1976).
The most lik e ly  explanation for the extended excretion time in the 
ra t was the occurrence of extensive b ilia ry  excretion and enterohepatic 
circu lation . B ilia ry  excretion was s ign ifican t in ra ts , 10-15% of the
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dose being recovered by 6h at 10mg-40mg/kg dose levels. The major 
b ilia ry  metabolite was 4'-hydroxy-4-biphenylylacetic acid, present 
as sulphuric, glucuronic and probably amino acid, conjugates. Smaller 
amounts o f 4-biphenylylacetic acid were eliminated in the b ile  both as the 
glucuronic acid conjugate and possibly an amino acid conjugate, although 
the la t te r  was not proved. This metabolite was probably recirculated  
as w e ll.
Enterohepatic circulation in the ra t was greatly diminished by 
pretreatment with either antib iotics or 1 ,4-saccharolactone. Both 
glucuronic acid and sulphate conjugates are known to undergo extensive 
hydrolytic cleavage in the in testine , especially the former, by the 
action of in testinal wall 8-glucuronidase and the sulphatase and 
8-glucuronidase a c tiv ity  of bacteria. Sulphatase a c tiv ity  of in testinal 
bacteria seems to be lim ited and the majority of sulphates pass through 
the intestine with l i t t l e  or no hydrolysis (Scheline,1968,1973; Garton 
and Williams, 1949; Hawkins and Young, 1954). Sulphatase ac tiv ity  
that has been observed in  the gut, for example with the sulphate ester 
anologue o f biscadoyl (Forth, e t  a t ,  1972) is due almost en tire ly  to 
microflora (Eriksson and Gustafsson, 1970). Another hydrolytic reaction 
of intestinal microflora is the cleavage of the amide bond of amino acid 
conjugates. Glycine is one of the more comnon amino acids involved, fo r 
example, £-aminohippuric acid is converted to £-aminobenzoic acid by ra t  
caeca! microorganisms (Scheline,1968). Amino acid conjugates of 4-hydroxy- 
41biphenylylacetic acid and 4-biphenylylacetic acid might therefore have 
been subjected to deconjugation and reabsorption.
B ilia ry  excretion and enterohepatic circulation were not studied 
in the rabbit, but the low level o f faecal radioactiv ity  recovered suggested 
that these processes were not s ign ificant in this species.
Another reason for the extended excretion time in the ra t , compared 
to the rabbit, could have been a difference in the extent of plasma 
protein binding. Many compounds are known to bind to plasma proteins 
(Truhaut, 1966; Goldstein, 1,949); those most readily bound are weak 
organic acids (or bases). Plasma protein binding is thus very common ' 
with many acidic anti-inflammatory agents, for example, indomethacin 
and phenylbutazone are 98% and 90% bound respectively (Shore, Brodie 
and HogBen, 1957). Bi phenyl yl acetic acid and 4'-hydroxy-4-biphenylyl- 
actic  acid would also be expected to be extensively bound. One consequence 
of this would be a reduced renal Clearance o f these metabolites, as only 
the unbound fraction would be free to transfer across the renal tubules. 
Reduced renal clearance due to plasma protein binding can lead to 
extended excretion times, and in some cases produce exceptional examples 
of drug persistence'. For example the x-ray contrast medium iophenoxic 
acid is so extensively bound that in low concentrations its  elim ination  
h a lf - l i fe  is 2.5 years (Astwood, 1957). In the case o f 4-biphenylylacetic  
acid and 4 '-hydroxy-biphenylylacetic acid and protein binding would 
undoubtedly increase the excretion time in both the ra t and the rabb it.
The e ffec t would, however, be less marked in the la t te r  because of the 
absence of s ign ificant b ilia ry  excretion and enterohepatic c ircu lation .
This would lead to conjugated metabolites being released into the blood 
rather than the b ile . Although conjugated metabolites are probably bound 
to plasma proteins, renal clearance would be less affected than with the 
free compounds. For example, i t  has been shown (Genazzoni and Pagnini, 
1963) that with sulphonamides, despite extensive plasma binding, the 
formation and excretion of glucuronic acid conjugates was not affected.
In the ra t only unbound metabolites are found in the blood, arising from 
either release into the blood from the liv e r  or by reabsorption from the 
in testine . Reduced renal clearance would thus be expected to be more 
marked in the rabbit.
The species differences in b ilia ry  excretion and plasma protein 
binding, and perhaps a difference in lip id  loca liza tio n , can thus account 
for the extended excretion time observed in the rat.compared to the 
rabbit.
Although the major metabolites of 4-ethynylbiphenyl have been 
isolated and identified  in this present study, the identity  of some o f  
the conjugated material remains unknown. Acid hydrolysis o f ra t b ile  
and rabbit urine resulted in the formation of 4'-hydroxy-4-biphenylyl- 
acetic acid and 4-biphenylylacetic acid. Trace amounts o f other 
metabolites were also formed, two being identified  as £-phenylmandelic 
acid and 4-acetyl biphenyl.
The phenolic metabolites of biphenyl are known to be conjugated 
with glucuronic acid (West e t u i .  1956; Block and Cornish, 1959; Raig 
and Ammon, 1970). Conjugation with sulphate has been less well studied 
and many important investigations into the metabolism of biphenyl 
(Meyer and Scheline, 1976a, b; Raig and Ammon, 1970, 1972) have only 
investigated the free metabolites produced by enzyme or acid hydrolysis. 
Recent studies with ra t hepatocytes (Wiebkin e t  a l .  1978) have shown that 
both glucuronic acid and sulphate conjugates o f 4-hydroxybiphenyl were 
produced and that the re lative  amounts varied with the level of hydroxylated 
substrate. At low levels of substrate (4-hydroxybiphenyl) these workers 
showed that sulphate conjugation was of major importance but with increasing 
substrate concentration glucuronic acid conjugation assumed the major ro le . 
This might explain the results of ra t b ilia ry  excretion in relation  to dose 
level (Figure 3 .7 ). At a dose level of 0.16 mg/kg 30% of the dose was 
excreted in the 6h, th is  was reduced to about S% at a dose o f 40 mg/kg.
A constant percentage o f the dose was excreted over 6h between 40 mg/kg 
and 100 mg/kg. Extending the results of the i n  v i t r o  studies of Wiebkin
e t  a l . to the present case one would expect sulphate conjugation to 
be more important at lower dose levels (perhaps 0.16-20 mg/kg).
Saturation of the sulphate conjugation system could have produced 
the fa ll  o f f  in the percentage of excreted radioactivity observed. 
Unfortunately i t  was not possible to isolate and identify  the conjugates 
in the b ile  from the dose response studies because of the low levels of 
radioactivity used. I t  would be interesting to repeat these studies 
with [35S] and investigate sulphate conjugation more thoroughly. There 
are very few quantitative studies of sulphate conjugation in the lite ra tu re , 
perhaps because of the d iff ic u ltie s  involved (Dodgson and Rose, 1970). 
Although phenolic sulphates are re la tive ly  metabolically stable and 
tend to be excreted as sulphates some hydrolysis can occur in the gut 
and bladder. Despite the s ta b ility  of aryl sulphates to enzymic 
hydrolysis excretion products can be d if f ic u lt  to isolate from urine and 
faeces because of th e ir la b il i ty  in acid conditions (Dodgson, Rose and 
Spencer, 1955). £-Nitrophenol sulphate, for example, undergoes auto- 
ca ta ly tic  hydrolysis that can be photochemically accelerated (Havinga, 
Dejongh and Dorst, 1956). In general sulphates are stable in a lka li but 
easily hydrolysed by acid. Small amounts o f the sulphate ester o f 4 1 - 
hydroxy-4-biphenylylacetic acid would therefore not be easily iso lated.
This might explain why in some cases urinary rad ioactiv ity  appeared to 
be conjugated but on re-chromatography of the material the free metabolite 
was observed.
Enzymic hydrolysis o f ra t b ile  with Ketodase (pure 3-glucuronidase) 
and aryl sulphatase (incubated with 1 ,4-saccharo-lactone to in h ib it unwanted
3-glucuronidase) showed that both glucuronic acid and sulphate conjugates 
of 4'-hydroxy-4-biphenylylacetic acid were present. I t  was not established 
whether the glucuronide was of the ester or ether type, or both. The
materials seemed quite stable in alkaline solution suggesting the ether 
1inkage,
(LS-0 —CH?C00H sulphate ester of 
4 1r hydroxy“4-bi phenylyl 
acetic acid
I I o . h C - 0 '/ H2C00H glucuronide (ether linkage) 
of 4 ,-hydroxy-4-biphenylyl- 
acetic acid
In addition to structures I and I I  above a s ign ificant fraction o f 
b ilia ry  rad ioactiv ity  (about 20%) occurred as a metabolite which was 
p a rtia lly  hydrolysed by 8-glucuronidase and aryl sulphatase and which could 
subsequently by hydrolysed with 4M HC1 to 4'-hydroxy-4-biphenylylacetic 
acid. This metabolite was probably a double conjugate in which both 
carboxylic and phenolic -OH groups were conjugated,
SO,
or
glucuronic 
acid
r -o-c 7 /\ V ch2c
\
Vx
X = unknown conjugate
The evidence from enzyme incubations showed that the phenolic group was 
conjugated with both sulphate and glucuronic acid, the former being more 
abundant. The conjugate of the acid function was not id en tified  alWiough 
a weak positive reaction was obtained with _p-dimethylaminobenzaldehyde, 
suggesting a glycine conjugate. Amino acid conjugation with aryl acetic  
acids is common, as discussed in Chapter I .  The above metabolite may well 
have been an amino acid conjugate that was further conjugated with glucuronic 
acid or sulphate. Double conjugates are known in drug metabolism (Parke,
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1968; Mi 11 burn, 1970} although they are not frequently observed. The 
phenomenon is usually observed when conjugation at one functional group 
does not increase the polarity of the molecule su ffic ien tly  to promote 
rapid excretion. Acetamidophenols and hydroxyanisoles, for example, are 
further conjugated with glucuronic acid or sulphate (Parke, 1968)..
Impaired renal excretion may increase the occurrence of double conjugates.
The phenolic sulphuric and glucuronic acid conjugates of 4'-hydroxy- 
4-biphenylylacetic acid in the ra t are lik e ly  to be strongly bound to 
plasma proteins and might be poorly excreted at the kidney and undergo 
further conjugation in the liv e r  followed by b ilia ry  excretion.
The overall picture o f b ilia ry  metabolites and th e ir  excretion and 
enterohepatic circulation is summarised in Figure 3.11.
The present work on the in  v ivo  metabolism of 4-ethynylbiphenyl 
makes i t  possible to speculate on the lik e ly  mechanisms of the pharmacological 
and toxic effects o f the compound. Preliminary animal t r ia ls  of Allen and 
Hanbury L td ., showed that 4-ethynylbiphenyl was a good anti-inflammatory 
agent but was ulcerogenic in ra t and dog, though not In raboit or 
marmoset.
4-Biphenyl acetic acid is a well known anti-inflammatory agent and 
has been shown to be the active metabolite o f several anti-inflammatory • 
drugs. For example, 4-methyl-2 - (4-phenylbenzyl)-2-oxazoline-4-methanol 
was shown to be extensively metabolized to 4-biphenyl acetic acid (Turnbull 
e t  a l . 1974), as was difenpiramide (Grassi e t  d l .  1977),
4-Methyl-2-(4-phenylbenzyl) -  
2-oxazoline-4-methanol
Cf-L 
I 3 
yN-C-CHo0H
'V' i 2
|  metabolism
Figure 3.11 . SCHEMATIC REPRESENTATION OF BILIARY EXCRETION 
AND ENTEROHEPATIC CIRCULATION IN RAT
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In both these cases further jnetabolism to the 4 ' -hydroxy derivative  
was observed and Grass! e t a l  Q 977) shov/ed that this metabolite was not 
pharmacologically active.
The anti-inflammatory a c tiv ity  of 4-ethynylbiphenyl can therefore 
probably be explained by its  metabolism to 4-biphenylyl acetic acid.
This metabolite and the 4 ‘ -hydroxy derivative were tested in the prostaglandin 
synthetase in h ib ito r te s t. The former compound was found to be active and 
the la t te r  inactive. This is discussed more fu lly  in Chapter 4 .
The ulcerogenic properties of 4-ethynylbiphenyl are also l ik e ly  to 
be due to 4-biphenylylacetic acid, and perhaps the 4 ‘ -hydroxy derivative.
As discussed in Chapter I ,  ulcerogenicity is a common s id e -e ffec t o f acidic  
anti-inflammatory agents. I t  would Be.interesting to compare the u lcer­
ogenicity of both 4-biphenylylacetic acid and 4 ‘ -hydroxy-4-biphenylylacetic 
acid to establish i f  jD-hydroxylation.reduces this action as i t  does the 
anti-inflammatory action.. This could Be tested in  v ivo  by many animal 
tests including histolo.gical studies and measuring faecal blood loss, or 
i n  v i t r o  by studying the.;effects on mucosal glycoprotein synthesis 
(Johnston e t  aZ.,1975).
The marked species difference in the toxic ity  o f 4-ethynylbiphenyl
\ >— v CH^ COOH
A
metabolism
o y-C H zCQNK ^
may be explained by differences in b ilia ry  excretion, enterohepatic c ircu latio  
and protein binding. The drug was toxic in the ra t and dog but not in  the 
rabbit or marmoset. The la tte r  two species were especially resistant to 
gastric ulceration whilst the dog was very sensitive. These two groups 
of species, rat and dog, rabbit and marmoset, fa l l  into to quite d is tinct 
categories of b ilia ry  excretors. Rat and dog are good b ilia ry  excretors 
(Group I in Chapter I )  and rabbit and marmoset are poor b ilia ry  excretors 
(Group I I ) .  The molecular weights of the conjugated metabolites o f 
4-ethynylbiphenyl fa ll  within the range 300-400 (F ig. 3.11) and would 
be expected to be sign ifican tly  excreted in the b ile  o f Group I species 
(upwards of 25%). Group I I  species on the other hand would be expected 
to excrete only minimal amounts of the conjugates (0-10%). I t  has been 
established that hydrolysis to free metabolites occurs in the gut, thus 
exposing the intestinal wall to the toxic agents, 4-biphenylylacetic  
acid and/or 4'-hydroxy-4-biphenylylacetic acid. The presence of entero­
hepatic c ircu lation, which was demonstrated in the ra t , would cause 
continual re-exposure o f the upper gastrointestinal tra c t to these 
metabolites.
Another s ignificant aspect o f b ilia ry  excretion and enterohepatic 
circulation is the ir e ffect on the levels o f toxic metabolites in the 
blood. As only the unconjugated metabolites are pharmacologically active 
i t  is the persistence of these that is important. In the rab b it, where 
b ilia ry  excretion was probably not important, conjugated metabolites were 
excreted in the urine. As discussed e a r lie r , the renal clearance o f 
of conjugates was l i t t l e  affected by binding to plasma proteins and these 
metabolites were quickly eliminated from the systemic c ircu lation . This 
v/ould leave re la tive ly  low levels of pharmacologically active unconjugated 
metabolite(s) in the blood which would account for the reduced toxic
(and possibly beneficia l) effect observed in the rabb it. In the ra t 
where the conjugated metabolites were preferentia lly  excreted into 
the b ile , levels of free metabolite in the blood were maintained by 
continual reabsorbance from the gastrointestinal tra c t.
4-Biphenylylacetic acid is a potentia lly useful anti-inflammatory 
agent, but the therapeutic indices of drugs that give rise to i t  depend 
on the ir biotransformations. These must be such that prolonged exposure 
of the gastrointestinal trac t to 4-biphenylylacetic acid and possibly 
4 '-hydroxy-4-biphenylylacetic acid, is avoided. In addition, species 
variation in the phase I I  metabolism and excretion of these metabolites 
can have marked effects on the therapeutic value of the parent drug.
This has been clearly  demonstrated with ethynylbiphenyl.
3.6 SUMMARY
1. 4-Ethynylbiphenyl was shown to undergo extensive metabolism 
in ra t and rabbit. Both aromatic hydroxylation and ethynyl group 
oxidation were demonstrated. No metabolites possessing an ethynyl 
group were isolated. These results are discussed in re la tion  to 
previously known metabolism of acetylenic compounds.
2. The two major excreted metabolites were the same in both 
species studied. The most important, 4-hydroxy-4-biphenylylacetic 
acid, accounted for 90-95% of the dose and 4-biphenylylacetic acid 
another 2-10%. The excretion patterns of the two species were markedly 
d iffe re n t.
- 3. B ilia ry  excretion and enterohepatic circu lation were
demonstrated in the ra t.
4. The above findings are discussed in relation  to the observed 
i n  v ivo  pharmacological and toxicologal effects o f 4-ethynylbiphenyl.
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4 .1  INTRODUCTION
4 .1 .i Metabolism Studies I n  V i t ro
The study of xenobiotic biotransformations i n  v i t r o  rather than 
i n  v ivo  enables controlled and closely defined investigations to be 
made into the mechanisms by which a compound is converted to its  metabolites. 
In many cases i n  v i t r o  studies identify  metabolic intermediates not seen 
i n  v ivo  and enables the ce llu la r location of metabolism to be determined.
There are a variety of i n  v i t r o  systems used for studying bio­
transformations, a ll o f which have advantages and disadvantages, including 
for example, organ perfusion, tissue slice incubation, cell cultures and 
suspensions, tissue homogenates and subcellular fractions. The systems 
used in the present study were homogenates and sub-cellu lar fractions of 
ra t liv e r  (normal and induced), and incubates of in testina l m icroflora.
4.1 . i i  Xenobiotic Metabolism by Intestinal Microflora
The importance o f intestinal microflora in hydrolysing b ilia ry  
conjugates has been recognised for many years (Barber, Brooksbank and 
Haslewood, 1948, ) .  Their role in the metabolic transformation o f
drugs, however, has only been appreciated in recent years. I t  is now 
thought that the xenobiotic metabolic ac tiv ity  o f the gut microflora 
might, in certain adaptive conditions, be equal to or greater than that 
of the liv e r  (Drasar e t  d l . 1970).
The distribution o f microorganisms throughout the gastrointestinal 
trac t varies considerably and there are also considerable inter-species 
differences (Drasar e t  a l . 1970; Williams e t  a l .  1971). Some of the more 
important differences are lis ted below:
a) The majority of the microflora population exists in the distal 
small intestine and the large intestine (Cregan and Hayward, 1953;
Williams e t  a l .  1971).
b) The germicidal action of the gastric secretions usually result in  
s te r ile  conditions in the stomach.
c) Gastric emptying affects the bacterial population of the proximal 
small in testine.
d) There is an important distinction between coprophagic and non- 
coprophagic animals.
e) In the mouse there is a non-secretory section of the stomach that 
is colonised with bacteria (Williams e t  a l .  1971).
The majority of the intestinal microflora are anaerobic (Sanborn, 
1931; Gorbach, 1971), and accordingly produce metabolic conversions th a t, 
are reductive (Drasar and H i l l ,  1974). I t  is s ign ificant however, that 
most work has been performed on aerobic or facultative aerobic bacteria , 
because o f th e ir re la tive  ease of isolation and cu ltiva tio n . The loss 
of a c tiv ity  associated with isolation of in testinal samples is d i f f ic u lt  
to estimate. I t  has been shown (Spears and Freter, 1967) that the s t r ic t  
anaerobes within the gut are sensitive to even transient contact with 
oxygen. Oxidation-reduction buffer systems that reduce losses of a c tiv ity  
during incubation have been developed (Moore, 1968; Col lee , Rutter and . 
Watt, 1971). Also the use of anaerobic incubation cabinets can increase 
the y ie ld  o f anaerobic bacteria by 100-fold (Drasar and H i l l ,  1974).
The degree of contact that foreign compounds have with in testina l 
bacteria/ is important, and depends on the route o f administration, rate
of absorption from the gut, and species of animal studied. Oral 
administration gives the greatest exposure but b ilia ry  excretion of 
parenterally administered compounds can lead to contact with the 
m icroflora. Lipophilic compounds administered ora lly  w ill be absorbed 
quickly from the gut and have re la tive ly  short exposure unless la te r  
b ilia ry  excreted.
Species differences in in testinal microflora can be very important, 
especially when comparing laboratory animals, such as the ra t , with man.
I t  is  mainly in the upper gastrointestinal tra c t that differences 
occur, due to d iffe ren t gastric secretory processes, in testina l m o tility , 
feeding habits and coprography (Drasar and H i l l ,  1974; Hawksworth e t a l .  
1971; Marsh, Alexander and Levvy 1952).
4.1 . i i i  Microsomal Drug Metabolism
Metabolism of foreign compounds by hepatic microsomes was f i r s t  
described by Mueller and M ille r (1949, 1953). They demonstrated that 
the microsomal fraction of a liv e r  homogenate .catalysed both the reductive 
sp littin g  of the azo-1inkage and the oxidative N-demethylation of amino- 
azo dyes. Brodie and his co-workers (1955) expanded these findings and 
showed that sim ilar enzymes located in the hepatic microsomes were 
responsible for effecting the metabolic transformation o f many drugs.
The subject has since received much attention and has been well reviewed 
(G ille tte  et a l .  1959; Estabrook e t  a l .  1973; LaDu, Mandel and Way, 1971; 
Remmer, 1970; Testa and Jenner, 1976; U llrich  e t a l .  1970).
The microsomal enzyme systems catalyse a variety of reactions 
(Parke, 1974b; Testa and Jenner, 1976), Most are oxidations although 
reduction of n itro  and azo compounds occurs. The v e rs a til ity  of the 
microsomal metabolizing system is easier to understand by considering
the oxidations to be due to one mechanism, that of hydroxyl a t i  on (Parke,
1968 } . For fu ll ac tiv ity  the hydroxylation system requires NADPH^ s
or an NADPH^-regenerating system, and molecular oxygen. Thus the
microsomal enzyme system is classified as a mixed-function oxygenase
(Mason, 1965] or monooxygenase (Hayaishi, 1964). The enzymes catalyse
the consumption o f one oxygen molecule per molecule of substrate, one
atom of the oxygen being reduced (to water) and the other appearing in
the oxidized substrate. The u tiliz a tio n  of molecular oxygen as opposed
to that of water was demonstrated by Posner, Mitoma, and Udenfriend (1961) 
18 18using 02 and H2 0. I t  is now known that the mixed function oxygenase 
system of the endoplasmic reticulum comprises several d iffe ren t enzymes 
but the NADPH^ -O^  dependent generation of ‘active oxygen' is probably 
common to a l l .
Although the exact mechanism by which the microsomal mixed function 
oxygenase operates are s t i l l  not certain the scheme shown below is widely 
accepted (e .g . Testa and Jenner, 1976; Hildebrandt and Estabrook, 1971;
Estabrook e t a l ,  1971)
SOH
(Fe )SH
(Fe )S0H
+++ [(Fe+ )(0 2) S H ] ^  [(Fe )(0 2 *)SH]
e~
S = substrate
SOH = hydroxylated substrate
The hepatic microsomal hydroxylating system has been shown to contain 
NADPH^ , a flavoprotein and a non-haeme iron protein, which together are 
thought to constitute the NADPH^ - cytochrome c dehydrogenase, and a 
haemoprotein known as CO-binding pigment or cytochrome P-450 (Omurae t  a l ,  
1965). Structural details of this complex are discussed in the review 
artic les  referenced e a rlie r .
D ifferent forms of cytochrome P-450 occur, as indicated by the 
d ifferen t spectral changes that occur when d iffe ren t types o f substrate 
bind, and by solubilization and chromatographic separation. Induction of 
microsomal enzyme a c tiv ity  by foreign compounds is well known and has 
been reviewed (Gelboin, 1971; Conney, 1967; Parke, 1968; Hathaway, 1972). 
There are at least two groups of inducing agents. The f i r s t  exemplified 
by phenbarbitone, increases the metabolism of a wide variety of substrates. 
The second group, exemplified by 3-methylcholanthrene and comprising mostly 
of polycyclic hydrocarbons, stimulates metabolism of a lim ited number o f 
substrates. Anabolic steroids appear to stimulate by d iffe ren t mechanisms 
(G ille tte , 1963, 1969 ) suggesting another group of inducers. There is 
evidence that there are d ifferen t mechanisms of induction (Mannering, 1971; 
Parke, 1974b). 3-Methylcholanthrene for example, gives rise to an 
in tr in s ic a lly  d ifferen t form of P-450, known as P-448 (or P^-450). Also, 
whereas phenbarbitone pretreatment produces increased type I and type I I  
binding spectra, only type I I  is increased by 3-methylcholanthrene (Kato, 
Takanaka and Takayanghi, 1970; Shoeman, Chaplin and Mannering, 1969).
Not a ll phase I metabolism of foreign compounds occurs w ithin the 
endoplasmic reticulum ( 'microsomes1) .  Mitochondrial amine oxidases 
convert amines to aldehydes, and the soluble fraction ( 'c e ll sap1) 
contains alcohol dehydrogenase, aldehyde oxidase and : xanthine oxidase, 
which oxidise alcohols and aldehydes. There are other enzymes, known and
unknown, that metabolize foreign compounds in the blood plasma, as well 
as those of the intestinal microflora.
The work reported here represents a preliminary investigation  
into the subcellular location(s) of 4-ethynylbiphenyl metabolism and 
the mechanisms by which the observed biotransformations occurred. The 
in  v iv o  studies reported in Chapter Three showed the major excretory 
products to be 4'-hydroxy-4-biphenylylacetic acid and 4-biphenylylacetic 
acid. I t  was hoped to establish whether 4 '-hydroxylation preceded 
ethynyl metabolism or v ice  versa , and whether any intermediates could 
be isolated.
•iv Ames Test
The Ames test (Ames, 1971; Ames e t  a l,  1975; Ames, Lee and Diirston,'i !
1973; McCann and Ames, 1975) is a re la tive ly  simple and sensitive test 
which detects the mutagenicity of chemicals towards bacterial c e lls . The 
compounds are tested on Petri plates with mutated forms o f  Salm onella  
typhimjAvivm m th  a requirement for h is tid ine , reversion to prototrophy 
is taken os an index of mutagenicity. Correlations between such mutagenicity 
and potential carcinogenicity have been claimed but th is is an area o f 
active speculation and discussion (Ashby and Styles, 1978). A review 
of the evidence available is beyond the scope o f the present study in 
which 4-ethynylbiphenyl was tested for mutagenicity. The study was 
considered worthwhile in view of possible epoxide formation in  the 
metabolism of the ethynyl group. Such an intermediate would possibly 
be a mutagen and carcinogen (see Discussion). Despite reservations about 
correlations between mutagenicity and carcinogenicity, the Ames tes t, and 
modified versions of i t ,  are useful 'early  warning1 i n  v i t r o  tests fo r  
possible carcinogens.
4 .1 .v In  V itro  Inhibition of Prostaglandin Synthetase
The possible roles of prostaglandins as mediators of the inflammatory 
response were discussed in the General Introduction. The inh ib ition  of 
prostaglandin synthesis and the connection with the mechanism o f action 
of many anti-inflammatory agents has been comprehensively reviewed (Flower, 
1974). Prostaglandin synthetase is a multi-enzyme complex associated 
with the endoplasmic reticulum or ‘microsomal frac tion1 (Van Dorp, 1967; 
Samuelsson, 1969). The complex catalyses the conversion of C-20 poly­
unsaturated fa tty  acids to various prostaglandins and hydroxyacids. Many 
tissues possess prostaglandin synthetase a c tiv ity  but the ram and bovine 
seminal vesicles are the richest sources. Consequently these tissues 
have been routinely used for characterization of reaction products 
Jiugteren e t  a l 1966; Hamberg and Samuelsson, 1967; Flower, Cheung, and 
Cushman, 1973) and for examining the mechanism of prostaglandin biosynthesis 
(Wallach and Daniels, 1971; Flower e t a l . 1973; Pangansmala e t  aZ-.1974).
rv
Microsomal fractions from these tissues are now widely used fo r screwing 
potential non-steroidal anti-inflammatory agents.
.1 .vi Chemical Models for Mono-Oxygenase Enzymes
Since the discovery by Udenfriend e t  a l .  (1954) that a mixture of 
F e C lI) ,  ascorbate and molecular oxygen could hydroxyl ate aromatic rings 
there have been numerous attemps to devise chemical model systems fo r  
the mono-oxygenase enzymes. Although such systems have given an insight 
into oxidation processes l i t t l e  has been learnt about the enzyme mechanism. 
There is a need for greater understanding of the interaction o f molecular 
oxygen with metal ions to produce 'active oxygen1 species involved in 
oxenoid mechanisms. The results obtained from studies with chemical 
models have been well reviewed (Jerina, 1973; U llrich  and Staudinger, 1969).
In the present study the oxidation of 4-ethynylbiphenyl was 
investigated using an Udenfriend-type system and Fenton’s reagent.
The Udenfriend system is considered to be one o f the best models for 
monooxygenases since i t  reacts with the correct stoichiometry and has 
a broad sp ec ific ity . The mechanism o f action is unclear* although i t  
is thought that reduction of oxygen to hydrogen peroxide does not occur* 
and hydroxylation is not mediated by the hydroxyl radical (HO*) or by 
superoxide (O ^  or H0£). Norman and Lindsay-Smi th (1965) have suggested 
a radical mechanism not involving HO*:-
0
Ascorbic acid
0 .  0=0 v 0-0*
/  N
F e  ------- '■ 1 Fe Attacki ng
\ *\ /
0 "
/ radi cal
Despite the recognised lim itations of these chemical models i t  was 
hoped that indications of the in  v ivo  mechanism of 4-ethynylbiphenyl 
metabolism might be discovered.
4.2 MATERIALS AND METHODS
Chemi cals
4 - [ 14C]Ethynylbiphenyl (specific a c tiv ity  0.327 mCi/mMol) was 
synthesized (Chapter Two). Chemical and radiochemical purity was checked 
before use by th in -layer chromatography and radioscanning (found >99.0% 
pure).
Isocitrate dehydrogenase was purchased from the Boehringer Corporation 
(London) Ltd. Is o c itric  acid (DL), NADP (from yeast, monosodiurn s a lt)  
were purchased from the Sigma Chemical Company, London. Yeast extract 
was obtained from the Difco Laboratories, D etro it, Michigan, USA, and 
proteose peptone from Oxoid L td ., London.
Animals
Male Wistar Albino rats (150 ± lOg) were used fo r a ll studies. 
In testinal contents were collected from adult ra ts , rabbits and guinea-pigs 
that had been resident in the Departmental Animal Unit fo r a t least 7 
days.
S c in tilla tio n  counting
Aqueous and non-aqueous samples were dissolved in 0.5 ml o f  water 
and 4 ml of a Synper/onic NXP-toluene-2,5-diphenyl oxazole s c in t i l la n t  
(Wood e t  a l .  1975), and radioactivity determined as described before 
(Chapter Two). Scrapings from s ilica -ge l th in -layer chromatograms were 
counted in a sim ilar system but with the addition of 4% th ixotropic gel 
(Packard Ltd.}
Mass-spectroscopy
Methods used for identification  of metabolites were as described in 
Chapter Two.
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. Incubations with Caeca! Contents
The i n  v i t r o  incubations of [ ltfC] ethynyl biphenyl with samples of 
caeca! contents were performed using methods adopted from those of 
Scheline (1966). Samples of caeca! contents were prepared by suspending 
the contents of a single caecum in 10 ml o f 0.1M phosphate buffer pH 7.4  
(previously degassed under vacuum). The supernatant a fte r standing for  
5 min was taken for incubation. The media for incubations comprised 
0.5% (w/v ) each of D-glucose, yeast extract, and proteose peptone in 
0.1M phosphate buffer pH 7 .4 . Aliquots of this media (10 ml) were 
placed into 25 ml Thunberg tubes and the contents s te rilize d  by autoclaving 
a t 110°C for 15 min (15 p .s . i . ) .
When cooled, test material and caeca! extract (1 .Oml) were added 
to the tubes. The tubes were immediately evacuated (o il pump) to remove 
any dissolved or gaseous oxygen. Nitrogen was then admitted from a 
n itro gen -filled  bladder. This evacuation and flushing procedure was 
repeated three times to remove as much oxygen as possible.
[14C]Ethynylbiphenyl was added in combination with pure unlabelled 
m aterial, the total amounts used ranged between 1-10 mg and contained 
0.5 -5 .0  yCi of rad ioactiv ity .
Bile samples (0.5 ml, containing 100,000 d.p.m. rad ioactiv ity  
were obtained from b ilia ry  cannulated rats (see Chapter Three).
Due to the inso lu b ility  of 4-ethynylbiphenyl in the media the 
compound was dissolved in dimethylformamide (10-50pl). A turbid  
suspension was produced which was maintained by incubating on a rotary 
mixer.
All incubations were a t 37°C for 48~72h. Incubations were performed 
(a) with caeca! extract, (5) with boiled caeca! extract, and (c) with 
added an tib io tics.
After incubation the incubates were extracted with ethyl acetate at 
pH 7.4 and at pH 4 .5 . These extracts were combined, evaporated under 
reduced pressure and the residues dissolved in ethyl acetate (100-500i.il) 
for analysis by th in -layer chromatography. Chromatography was in solvent 
systems A and F (Chapter Three). Radioactivity was detected by radio­
scanning and radioautography as described in Chapter Three. Carboxylic 
acids were detected by spraying with 0.04% bromocresol green in ethanol 
(Lugg and Overall, 1948).
A larger scale preparation o f the metabolite formed from 4-ethynyl­
biphenyl was performed for iden tifica tion  by mass-spectroscopy. . The 
caeca! contents o f 5 rats were suspended in 50 ml o f cooled, s te r ilize d  
medium. 45 ml o f the supernatant were added to a flask containing 300 ml 
medium and 40 mg ;4 - [r 4CJethynylbiphenyl (5pCi). A fter flushing with 
nitrogen the flask was tig h tly  stoppered and incubated at 37°C for 7 
days. Ethyl acetate extraction was as described above. The concentrated 
extract was purified by column chromatography (s ilica -g e l 80-230 mesh,
20 x 2.0 cm column, toluene (5):petro1eum ether 60-80 (95) as eluting  
solvent). The fractions containing the metabolite (determined by th in -  
layer chromatography in the same solvent system) were combined and 
concentrated by rotary evaporation. The final purification was by 
preparative th in -layer chromatography. About 60ug of the metabolite 
was isolated and purified for mass-spectroscopy.
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4 .2 . i i Studies Us i ng Udenfri end *s Sys tern
The incubation system used was a modification of that described 
by Udenfriend e t a l .  (1954). The solutions were made up using 0.1M 
phosphate buffer (pH 5.5} to give final concentrations as follow s:- 
ferrous sulphate 10 mM, EDTA 30 mM, and ascorbic acid 50 mM. [1£fC]-- 
Ethynylbiphenyl [500pg, 1 .IpCi] was added in dimethylformamide (lOOyl) 
to 10 ml aliquots of the incubation medium to give a fin a l concentration 
of 0.3 mM. Incubation was a t 35°C for 1 Oh. Control incubations using 
buffer alone were performed.
At the end of the incubation period the rad ioactiv ity  was extracted 
with ethyl acetate (4 x 20 ml) and the combined extracts concentrated 
and investigated by th in-layer chromatography (solvent systems A and 
F, Chapter Three).
4 .2 .i i i  Studies with Rat Liver Preparations
The metabolism of 4-ethynylbiphenyl was studied using ra t l iv e r  
microsomes, 10,000g supernatant, and 10G,000g supernatant (soluble 
frac tio n ). These preparations were made using livers from male Wistar 
Albino rats (150 + lOg) that were a) normal, b) phenobarbitone pretreated 
(70 mg/kg intraperitoneally dosed twice daily for 4 days prio r to 
experiments), and c) pretreated with 3-methylcholanthrene (20 mg/kg daily  
fo r three days).
a) Preparation of liv e r  fractions
Rats were k illed  by cervical dislocation and the livers  quickly 
excised into ice-cold KC1 solution (1.15% w/v ) .  The livers  were blotted  
dry on f i l t e r  paper and weighed. A 25% homogenate was prepared by
scissor-chopping and homogenising in ice-cold KC1 (1.15% w/v ) using a 
motor-driven Potter-Elvehjem glass-teflon homogeniser (4 complete 
slow strokes). The homogenate was centrifuged at 10,000 g (MSE Higha V
Speed 18 centrifuge) for 20 min, the supernatant decanted and used
for metabolism studies. Microsomes were prepared by centrifugation of.
the 10, 000gav supernatant at 100,000gav (Beckman L5-65 Ultracentrifuge)
fo r 60 min. The supernatant (called 100,000g supernatant or soluble
fraction) was used in metabolism studies. The p e lle t was resuspended
in KC1 (1.15% w/v ) using a Potter-Elvehjem homogeniser (hand held, 3
strokes) and recentrifuged a t 100,000g for 60 min. The washedav
microsomal p e lle t was f in a lly  resuspended in phosphate buffer (0 .IM , 
pH 7.4) to give a concentration equivalent to lg liv e r  per ml.
b) Studies with 10,Q00g supernatant
Aliquots of 10,000g supernatant (2 .0 ml, equivalent to 0.5g liv e r )  
were incubated with ethynyl biphenyl (1 x 10  ^ a.p.m ., 0.63 mM) 
dissolved in 1Opl o f dimethylformamide,isocitrate ( 10 nM ) ,  NADP (1.0 nM ) ,  
isocitra te  dehydrogenase ( 0 .2  mg) 9 and MgSO^  ( 20 nM ) .  Incubations were 
a t 37°C in a shaking water bath in a ir  (10 ml conical flasks without 
stoppers) for Imin - 1 hour.
c) Studies with 10Q,000g supernatant
Aliquots of 100,000g supernatant (2 .0 ml, equivalent to 0.5g liv e r )  
were incubated with [1IfC]ethynylbiphenyl (as described above), glucose-6-  
phosphate (1 2  nM ) ,  glucose-6-phosphate dehydrogenase (0.25 mg), MgCl^
( 20 nM ) .
d) Studies with microsomes (100,000g p e lle t)
Aliquots of microsomal suspensions (2.0 ml, equivalent to 4 mg of 
microsomal protein) were incubated with [14C]ethynylbiphenyl (as described 
above), isocitra te  ( 10 nM ) ,  isocitrate dehydrogenase ( 0.2 mg), MgSO^
( 20 nM ) and NADP (1 .0  nM ) .  In al 1 cases the reaction was started by 
addition of [ 14CJethynylbiphenyl a fte r a pre-incubation of microsomes 
+ cofactors for 2 min at 37°C. Incubations were carried out for time 
periods of 1 , 3, 10, 15, 20,. 30 and 60 min. The reaction was stopped 
by the addition of 1ml ice-cold acetone followed by freezing at -60°C ' 
in a methanol bath.
d) Extraction of metabolites
The frozen incubation mixtures were freeze-dried and extracted 
with ethyl acetate/methanol (1:1 V/ v ) . Freeze-drying was complete 
within 6h and preliminary checks were performed to investigate possible 
loss of rad ioactiv ity  due to sublimation at the very low vapour 
pressures obtained. No significant loss of rad ioactiv ity  was observed 
a fte r  6h ( <1.0%) but samples le f t  overnight lost between 1-5% of radio­
a c tiv ity .
The organic extracts were dried under a stream o f nitrogen and 
redissolved in 600pl o f the same solvent. Aliquots (50pl) were taken 
for th ir-la y e r chromatography.
e) Thin-layer chromatography and determination of rad ioactiv ity
Thin-layer chromatography was performed using aluminium plates 
coated with s ilica -g e l (Merck, Darmstadt. Supplied by Schiecher and Schdll, 
London).
Plates were run in solvent system A and metabolites located by methods 
previously described (Chapter Three).
To quantitatively determine the amounts of metabolite present the 
aluminium plates were divided into 0.5 cm strips and each of these then 
cut into small pieces which were added to 4.0 ml s c in tilla t io n  flu id  with 
0.5ml water. Radioactivity was determined by s c in tilla tio n  counting.
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Preliminary checks showed that there was no s ifn if ic a n t absorption 
of rad ioactiv ity  onto the aluminium backed s trip s , and >99% of the 
rad ioactiv ity  was released .into the s c in tilla tio n  f lu id .
From the results histograms of rad ioactiv ity  o f sections of a 
th in -layer chromatogram were drawn and compared with a radioscan. This 
enabled an accurate determination of metabolites, e ither in terms of 
rad ioactiv ity  or as pg equivalents of 4-ethynylbiphenyl.
Inhibition of Prostaglandin. Synthetase In  V itro
Samples of 4-biphenyl acetic acid, 4-hydroxy-4-biphenylylacetic acid, 
and ethynylbiphenyl were investigated using an in  v i t r o  assay of prosta­
glandin synthetase inh ib ition . This work was performed at Allen and 
Hanbury L td ., Ware, Hertfordshire, England, by Dr. P. McCabe. B rie f 
details of the methods used are given below:
a) Enzyme preparation.
A crude lyophilised preparation of prostaglandin synthetase was 
prepared from ram seminal vesicles by the method of Flower e t  a l .  (1973).
b) Assay procedure
The assay procedure was that o f Flower e t a l .  (1973). The incubation 
mixture contained the following in 1.5ml capacity, p lastic  Eppendorf 
tubes (open during assay):
Final concentration
Adrenaline 5 mM
Reduced Glutathione 5 mM
Water + test compound
200 mM Tris-HCl buffer (pH 8.2)
[3HJ-Arachidonic acid a) 10 pM
b) 7.5 pM
c) 5.0 pM
100 mM
Enzyme 50pl ( e20-25 pg protein)
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The experiment was started, a fter pre-incubation, by addition of 
the enzyme and continued at 37°C for 5 min. The reaction was terminated 
by addition o f 75pl HC1 (4M).
Radioactive precursor (arachidonic acid) and prostaglandins were - 
extracted with ethyl acetaite and separated by column chromatography by 
the methods of White and Glassman (1975) and H il l ie r  and D illey  (1974). 
The production of prostaglandins was measured by s c in tilla tio n  counting.
4 .2 .iv . I n  V it ro  Mutagenicity Studies (Ames Test)
The possible mutagenicity of 4-ethynylbiphenyl in a modified Ames 
test was investigated. The work was performed by Miss Susan Hubbard, 
University of Sussex, Brighton, England.
The methods used were as described by Ames, McCann and Yamasaki 
(1975), with the exception that the levels of h istid ine were reduced 
in order to obtain a lower rate of spontaneous reversion.
As 4-ethynylbiphenyl was insoluble in the medium i t  was added in 
DMSO at a level o f 400yg/plate. Addition to soft agar caused 
precipitation of the drug but a solution was achieved by rotary  
mixing.
The bacteria used was Salmonella Typhvruvium TA98. For metabolic 
activation S9 (9000g supernatant) from rat liv e r  induced with Aroclor 
1254 was used.
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4 . 3  RESULTS
4 .3 .1 . Metabolism By The Gastrointestinal Microflora
a) Bile samples
B ilia ry  metabolites of 4-ethynylbiphenyl: were p a rtia lly  deconjugated 
by incubation with caeca1 incubates. The pattern of hydrolysis was very 
sim ilar to that observed with 3-glucuronidase and sulphatase preparations 
(Figure 3.9 . Chapter Three). Thin-layer chromatography showed that 
4'-hydroxy-4-biphenylylacetic acid and 4-biphenylylacetic were released, 
the la t te r  in small amounts only. No new metabolites were observed.
Upon acid hydrolysis of the material remaining conjugated a fte r  incubation 
these two acids accounted for about 90% and 7% respectively of the 
radioactivity present.
b) Ethynylbiphenyl
Only one metabolite of 4-ethynylbiphenyl was isolated from the 
incubations with caeca! contents. This was only isolated from large 
scale incubations (500 ml) and in very small amounts (approximately 
10-15 yg/incubation). Mass spectroscopy (see Appendix) indicated the 
compound to be 4-vinylbiphenyl (M/e 180
\V-CH=CH2
4 .3 .i i . Inh ib ition Of Prostaglandin Synthetase
I t  was shown that 4'-hydroxy-4-biphenylylacetic acid was v ir tu a lly  
inactive as an inh ib itor of prostaglandin biosynthesis in the system 
used whilst 4-biphenylylacetic acid possessed moderate a c tiv ity :
Compound Ki Kinetics
4-Biphenyl acetic acid
4'-Hydroxy-4-biphenylyl- 
acetic acid
4 x TO"5!.! 
Inactive
Competitive 
( <10% a t 10"4M)
The parent compound, 4-ethynylbiphenyl was very insouble and gave no 
measurable inhib ition o f synthesis a t saturation.
4 . 3 - i i i . Studies With Udenfriend*s System
Incubation of 4-ethynylbiphenyl with Udenfriend's system resulted 
in the production of 4-biphenylylacetic acid. The identity  o f this  
product was confirmed by co-chromatography and mass-spectroscopy (see 
Appendix).
No detectable amounts of 4'-hydroxy-4-biphenylylacetic acid,
4 '-hydroxy-4-ethynylbiphenyl, or any other metabolites were observed.
4 .3 .iv . Metabolism By Rat Liver Preparations
a) 10,000g Supernatant
Thin-layer chromatograms of extracts of these incubations showed 
that metabolism occurred and that several metabolites were produced. 
The major metabolite was 4-biphenylylacetic acid,
This identity  was confirmed by co-chromatography with authentic 
4-biphenylylacetic and comparison by mass-spectroscopy with £-phenylmandelic
acid and 4 ‘ -hydroxy-4-b iphenyly1acetic acid.
Other metabolites were observed but accounted for less than 10% 
of the total metabolite rad ioactiv ity . Chromatography radioscans are 
shown in Figure 4.1 . In this Figure, radioscan I shows a typical 10 min 
incubation extract, where 4-biphenylylacetic acid is seen to be the 
major metabolite. Radioscanning at greater se n s itiv ity , I I ,  shows the 
presence of at least three minor metabolites. At 40 min, I I I ,  radioscanning 
a t high sens itiv ity  shows the presence of at least five minor metabolites. 
One of these very minor metabolites (metabolite a) was found to 
co-chromatograph with 4 ‘ -hydroxy-4-biphenyly1 acetic acid.
b) 100,000g supernatant (soluble fraction)
4-Biphenylylacetic acid was the only metabolite observed in these 
studies. I t  was produced in very small amounts (<0.1 pg/0.5 g liv e r  
equivalent) and was only isolated in incubations of greater than 
40 min duration.
c) Microsomal fraction
In normal microsome preparations, phenobarbitone induced, and
3-methylcholanthrene induced, the major metabolite was 4-biphenylylacetic  
acid. There were several minor metabolites but as in the case o f the 
10,000g supernatant they accounted for less than 10% of the to ta l 
metabolite rad ioactiv ity .
The metabolism of 4-ethynylbiphenyl was s ig n ifican tly  induced by
both phenobarbitone and 3-methylcholanthrene. The rate o f production
<\tid
o f 4-biphenyly!acetiCy(was linear between 1-10 min in the induced 
microsomes and 20 min in the normal microsomes. During the lin e a r  phase 
the rate of production of 4-biphenylylacetic acid (n mol produced/mg 
microsomal protein/min) was increased approximately s ix -fo ld  by both
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Figure 4 .1 . Radioscans of in  v i t r o  incubations with 
109000g supernatantTof ra t liver
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inducing agents (Figure 4 .2 .)
4*3 .v. Ames Test
The results of this study were as follows:
Compound Revertants TA98/plate*
-S9** + S9
4-Ethyny1bipheny1 33 77
(400 yg/plate)
*  A fter subtraction  o f spontaneous reversions (controls) 
* *  S9 = 9S000 g supernatant (induced ra t liv e r  homogenate)
Mutagenicity was observed both without and with 'activation ' by 
9,000g supernatant. The reversion rate was very low though activation  
produced a higher incidence.
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4 .2 . Metabolism of 4-ethynylbiphenyl in microsome- 
preparations of ra t l iv e r .
15
Time [min)
20 25 30105
abolism of 4- [ 14C]ethynylbiphenyl in microsomes from ra t l iv e r  (normal 
induced) was measured at several time points up to 30 min. Results are 
^essed as nmoles of 4-ethynylbiphenyl metabolised/mg microsomal protein 
are the mean + s.e.m. for four rats .
©—® Induced with 3-methylcholanthrene 
o—o Induced with phenobarbitone 
* —-a Normal
4.3 . DISCUSSION
The in.vitro hydrolysis of radioactive b ilia ry  conjugates of
4-ethynylbiphenyl by gastrointestinal microflora suggested that the
in  vivo  observation of enterohepatic circulation was due also to bacterial
14hydrolysis. Incubation of [ C] ethynylbiphenyl with the microflora 
produced only one metabolite, 4-vi nylbiphenyl. This compound was not 
found in control incubates of boiled bacterial suspensions. The acetylene 
group had been reduced by a two electron reduction to the alkene analogue:
:h=ch
4-Vinylbiphenyl4 -E thy ny 1b i phe ny1
Reduction of acetylene to ethylene is well known in some bacteria and 
the reaction is used as a method of assaying nitrogen fixation  in plants 
(Dilworth 1966; Schbllhorn and Burns 1966). The nitrogen molecule is  
very sim ilar to that of acetylene, being linear and possessing a tr ip le  
bond of sim ilar dimensions. I t  is interesting to note that acetylene 
has been shown to competitively in h ib it nitrogen fixation (Dilworth 1966). 
Although no work appears to have been performed on acetylene and acetylenic 
compound metabolism by gastrointestinal microorganisms, i t  seems 
reasonable to suppose that sim ilar reductionswould occur. Using 
deuterated water Dilworth (1966) showed that the two electron transfer 
did not involve the acetylide ion HCeC* as an intermediate, for the 
ethylene produced was not tri-deuterated. The reduction of acetylene 
is highly anaerobic and strongly inhibited by oxygen. I t  is probable 
that in aerobic arganisms that exhib it the reduction, the process occurs 
in an oxygen-free microenvironment (Brock 1974). There are several 
species of bacteria within the gastrointestinal trac t that possess
nitrogenase a c tiv ity  (K le b s ie lla , spp, & c io s tr id u n  spp .) which may have 
been responsible fo r the reduction of 4-ethynylbiphenyl (Drasar and 
H i l l , 1974).
I t  is d if f ic u lt  to estimate the importance o f this reduction in vivo, 
fo r although only very small amounts of the vinyl compound were produced 
in  v i t r o  this may have been due to oxygen contamination (see Introduction) 
Neither 4 -vinyl biphenyl or its  lik e ly  metabolites (c f. styrene, El Masry, 
Smith, Williams 1958), 4-biphenyly!glycol and £-phenylmandelic acid 
were isolated in  v ivo  (except for small amounts o f the la t te r ) .
The contribution of the gut microflora to the metabblism of 4-ethynyl- 
biphenyl seems, therefore, to be small, although the hydrolysis o f its  
conjugated metabolites was significant/...
The results o f the prostaglandin synthetase inhib ition study
(X C ij
demonstrated clearly that whilst 4-biphenylylacetic^was a moderate 
in h ib ito r the 4 '-hydroxylated derivative was inactive. The parent 
compound, 4-ethynylbiphenyl was too insoluble to o test s a tis fa c to rily , 
but was inactive at saturation levels. I t  seems lik e ly  that the 
anti-inflammatory ac tiv ity  of 4-ethynylbiphenyl in  v ivo  is due mainly 
to the acidic metabolite before hydroxylation. in  v ivo  testing o f 
4-biphenylylacetic acid and 4'-hydroxy-4-b iphenyly!acetic acid is  
necessary to confirm the in  v i t r o  results before defin ite  conclusions 
can be made, although Grassi e t a i .  (1977) have stated that the 
4 ‘ -hydroxylated derivative was pharmacologically inactive (unfortunatley
OH
•CH-COOH :h- ch2oh
p-Phenylmandelic acid 4-Biphenyly! glycol
without specifying tests used). Aromatic hydroxylation is a widely 
observed mechanism of drug inactivation (Williams 1959; Testa and 
Jenner 1976), although does not always produce total loss of a c tiv ity . 
Phenylbutazone, fo r example, is metabolised to oxyphenbutazone which 
possesses anti rheumatic properties sim ilar to the parent compound, and- 
is probably responsible for much of the a c tiv ity  in  v iv o .
Phenylbutazone Oxyphenbutazone
Phenobarbitone, on the other hand, is to ta lly  inactivated by £-hydroxylati
The results o f the Ames test showed that 4-ethynylbiphenyl was 
mutagenic in the system used both with and without 'activation* by 
9,000g ra t liv e r  supernatant (S9 ) .  Although activation doubled the 
reversion rate , the level observed was exceedingly low, about 8 
revertants/10 yg 4-ethynylbiphenyl (0.007 revertants/n mole). Comparison 
of these results with those compiled by McCann, Choi, Yamasaki, and 
Ames (1975), shows them to be sim ilar in order to those obtained with 
non-carci nogens such as: benzoic acid and s a lic y lic  acid. in  v i t r o
tests such as the Ames test would need to be supported by in  v ivo  
carcinogenici ty and teratogenenicity studies, before firm  conclusions 
regarding the safety of 4-ethynylbiphenyl can be drawn.
The mechanism of ethynyl group metabolism remains unproven. However, 
the simple addition of water suggested by El Masry e t a i .  (1958) with 
phenyl acetylene seems untenable.for ethynylbiphenyl. The reaction 
is catalysed by the microsomal monooxygenase system, induced by
phenobarbitone and 3-methylcholanthrene, and inhibited by carbon monoxide. 
The oxidation therefore probably proceeds by addition o f oxygen across 
the carbon-carbon tr ip le  bond. The formation of epoxides in the metabolic 
oxidation of double bonds is well established (Daly, Oerina, and Witkop, 
1972; Oerina and Daly 1974) and a sim ilar process seems lik e ly  to occur 
with e thy nyl groups. The s ta b ility  of the epoxide formed, however, 
would be much less than fo r the correspond!*ng alkenes and would probably 
rearrange immediately to the ketene:
0
CSCH C -  CH
4 -Ethynylb i phe nyl
spontaneous
rearrangement
— / /  CH=C=0
The very reactive ketene thus produced would hydrolyse on contact with 
water to produce the corresponding acid:
CH=C=0
H20 *■?>» m H2-C00H
4-Biphenylylketene 4-Biphenyly!acetic acid
Such a mechanism involving unstable or reactive intermediates would 
explain the fa ilu re  to isolate intermediate metabolites both in  v iv o  and 
in  v i t r o .
The mechanism of phenyl acetylene oxidation suggested by El Masry, 
Smith, Williams (1958) involved the asymmetrical addition of water 
(contrary to the Markovnikov p rin c ip le ). This would in  the case o f 
4-ethynylbiphenyl produce an aldehyde intermediate:
4-Ethynyl biphenyl
h2o
-C=C-H
unstable vinyl alcohol 
intermediate
4-Biphenylylacetaldehyde
To produce the acid derivative this aldehyde would have to be 
oxidized, a reaction, that is associated with the enzymes o f the soluble 
fraction of l iv e r  homogenates such as aldehyde oxidase, xanthine oxidase, 
and alcohol dehydrogenase (Parke, 1968). The production of 4-biphenylylacetic  
acid however occurred readily in washed microsomes thus ruling out the 
above mechanism. The symmetrical addition of water to 4-ethynylbiphenyl 
would resu lt in the formation of a ketone, the oxidation of which again 
requires the enzymes o f the soluble fraction . The oxidation products 
of such a ketone intermediate, as well as the ketone i t s e l f ,  v/ere 
isolated in trace amounts in  vivo, suggesting that this might represent 
a minor route of metabolism:
ChCH
4-Ethynylbiphenyl
-CH-CH3 
OH
4-Biphenylylmethyl-  
carbinol
4-Acetyl biphenyl
-CH-COOH 
QH .
p-Phenyl-
mandelic
acid
C-CH.
¥
-C00H
4-Biphenyly!-  
carboxylic 
acid
Support fo r the epoxide mechanism is found in the work o f McDonald
and Schwab (1964) who studied the peroxidation of acetylenes. These 
workers showed that phenyl acetylene was oxidized to phenyl acetic acid 
by trifluoroperacetic acid and produced evidence fo r the formation of 
a ketene intermediate, although neither this or the oxirene precursor 
were stable enough to iso late. Also, i t  is interesting that in the 
present study Udenfriends system produced 4-biphenylylacetic acid 
from 4-ethynylbiphenyl with no apparent intermediates.
The lik e ly  mechanism for the in  v iv o  and in  v i t r o  metabolism of 
4-ethynylbiphenyl is shown below:
Ar -  € 3= C -  H 4-Ethynylbiphenyl
Endoplasmic
reticulum
cyt.P-450
0 ^'Active* or ‘s in g le t1 oxygen)
.0
Ar -  C = C -  H
unstable oxirene 
i ntermedi ate
spontaneous rearrangement
Ar -  CH = C = 0 very reactive  ketene intermediate
h2o
-OH
Ar -  CH = C 
i
s '
^OH 
isomerization
/ /
Ar -  CH0 -  C 
L \
0
4-Biphenyly!acetic acid
OH
Many aromatic and olefiniccompounds are converted by epoxidation 
intermediate arene and alkene oxides by mammalian monooxygenases. Due 
to th e ir highly electrophilic  reac tiv ity  such oxirenes can bind to
proteins, RNA, and DMA. This property strongly implicates these 
intermediate epoxides as mutagenic and/or carcinogenic agents. Their 
effectiveness depends on several factors, such as the s ta b ility  of the 
epoxide towards spontaneous (or enzymic) degradation and on its  
e lectroph ilic  reac tiv ity  (Daly, Jerina, Witkop 1972; Oesch 1973; Jerina 
and Daly 1974).
I f  the epoxide intermediate does occur in the metabolism o f 
4-ethynylbiphenyl and other acetylenic xenobiotics, what is the likelihood  
of th e ir  being mutagenic or carcinogenic? The postulated oxirene of 
4-ethynylbiphenyl would be a very strained structure with a very short 
l i f e .  Consequently the rearrangement to the ketene would probably 
occur before any interaction with proteins or nucleic acids was possible. 
Enzymic hydrolysis by e^poxide hydrase, an enzyme thought to be closely 
associated with the endoplasmic reticulum (Daly, Jerina, Witkop 1972;
Oesch 1973), would be unlikely to occur with a short-lived epoxide 
intermediate and the products of such hydrolysis would not be observed. 
i n  v i t r o  mutagenecity studies, a lb e it very lim ited, showed 4-ethynylbiphenyl 
to be an exceedingly weak mutagen, comparable to results obtained by 
other workers using benzoic acid or s a lic y lic  acid (McCann, Choi,
Yamasaki, and Ames 1975). Biphenyl has not been tested in such systems 
but i t  would be interesting to compare results of this compound with 
those of 4-ethynylbiphenyl.
In conclusion, results from in  v i t r o  metabolism studies have indicated 
that in ra t liv e r  subcellular fractions 4-ethynylbiphenyl is readily  
metabolised by the monooxygenase enzyme system to 4-biphenylylacetic  
acid, probably v ia  a short-lived epoxide intermediate. Metabolism was 
not observed in the soluble fraction of liv e r  homogenates. More general 
aspects of acetylene oxidation are discussed in Chapter 5.
CHAPTER FIVE
GENERAL DISCUSSION
DISCUSSION
The in it ia l  aims of the project have been largely achieved (see 
Introduction). Thus, the metabolic profiles of 4-ethynylbiphenyl in both 
ra t and rabbit have been elucidated using l^C-labelled 4-ethyny-biphenyl 
and its  major metabolites which were synthesised for this work. I t  is 
suggested that the pharmacological and toxicological properties o f the 
drug can be attributed to the formation of 4-biphenylylacetic acid and 
4 ‘-hydroxy-4-biphenylylacetic acid as metabolites. In addition, the 
oxidation of the ethynyl group has been confirmed by in  v i t r o  studies 
and probable mechanisms involving an intermediate epoxide are proposed.
The in  v i t r o  studies showed that the ethynyl group is readily metabolized 
and occurs preferen tia lly  to 4 ' -hydroxylation.
4-Ethynylbiphenyl is metabolized in  v ivo  to produce two principal 
metabolites, 4'-hydroxy-4-biphenylylacetic acid and 4-biphenylylacetic  
acid. The la t te r  accounted for 10% or less of the excreted rad ioactiv ity  
and always appeared as the secondary metabolite in plasma and b ile . In  
the in  v i t r o  studies, however, 4-biphenylylacetic acid was the major 
metabolite observed. I t  seems lik e ly  that in  v ivo  4-ethynylbiphenvl is  
f i r s t  metabolized to 4-biphenylylacetic, which may undergo 4 '-hydroxyla tion  
prior to leaving the liv e r  via the blood or b ile . These phase I metabolites 
undergo conjugation and the extent o f subsequent b ilia ry  excretion and 
enterohepatic recirculation is probably responsible for the species 
variation observed in gastrointestinal to x ic ity  (see Discussion, Chapter 
Three).
Whilst 4-ethynylbiphenyl is too insoluble for satisfactory testing  
as an anti-inflammatory agent in an in  v i t r o  prostaglandin synthetase 
inh ib ition  te s t, 4-biphenylylacetic acid is found to be a moderately strong
in h ib ito r whereas 4*-hydroxy-4-biphenylylacetic acid is inactive (see 
Chapter Four). Further, in  v iv o , tests such as the adjuvant induced 
a rth r it is  test, the cotton pe lle t granuloma tes t, and the u ltra -v io le t  
erythema test are necessary'to correlate these in  v i t r o  results with 
anti-inflammatory a c tiv ity  in  v ivo .
The damaging action of acidic anti-inflammatory agents on the 
gastrointestinal trac t is well known (see Chapter One), and i t  would 
be interesting to compare the effects of the two acidic metabolites 
in  this respect. Both histological studies and in  v i t r o  studies of 
the inhibition of gastric mucosal glycoprotein synthesis should be 
performed. I f  gastrointestinal ulceration is  mediated by prostaglandins 
(see Introduction) then 4 ’-hvdroxy-4-biphenyly!acetic acid should be 
the least toxic of the two metabolites, unless i t  acts by a d iffe ren t 
mechanism. Results of such work might help elucidate the mechanisms of 
gastrointestinal inflammation and ulceration.
The rapid metabolism of 4-ethynylbiphenyl in both species studied 
contrasted with results of metabolic studies of other acetylenic compounds, 
fo r example phenyl acetylene (El Masri, Smith, and Williams 1958), and 
ethinimate (MacMahon 1958). I t  seems lik e ly  that the total molecular 
structure of the acetylenic compound influences whether or not metabolism 
of the tr ip le  bond occurs and also determines the rate o f such metabolism. 
Phenylacetylene, in contrast to 4-ethynylbiphenyl, is only slowly 
metabolized and i t  is probable that the presence of a second aromatic 
ring confers greater lip o p h ilic ity  upon the la tte r  compound increasing 
the degree of binding to the endoplasmic reticulum and thus enhancing 
metabolism.
A lternatively , oxidation of the tr ip le  bond in phenylacetylene might
occur by a d ifferen t mechanism to that of 4-ethynylbiphenyl. Including 
evidence from the present work there seem to be three routes of 
metabolism involving acetylenic groups.
These are, a).oxidation by monooxygenase enzymes of the endoplasmic 
reticulum, b) d irect hydration of the tr ip le  bond and subsequent oxidation 
in the soluble fraction , and c) hydroxylation a- to the tr ip le  bond. 
Monooxvgenase oxidation of the tr ip le  bond in 4-ethynylbiphenyl has been 
shown to be the most important mechanism in  v i t r o  (Chapter Four), and 
i t  is probable that the same mechanisms are responsible fo r the in  v ivo  
formation of 4-biphenylylacetic acid. However, the discovery o f very 
small amounts of 4-phenylmandelic acid and 4-acetyl biphenyl in  v ivo  
suggests that a minor pathway involving b) above occurs. This is the 
pathway suggested by El Masri, Smith, and Williams (1958) to explain the 
formation of phenylacetic acid from phenylacetylene, when traces of 
mandelic acid were found. In the lig h t of the present evidence from 
4-eth)pbiphenyl metabolism, however, i t  seems possible that phenylacetylene 
might also be metabolized principally by the monooxygenase system. 
C larifica tion  of the mechanisms involved in acetylenic oxidation could 
be obtained by in  v i t r o  studies using 1802 . I f  the epoxide mechanism 
proposed e a r lie r  (Chapter Four) is correct, then the 4-biphenylylacetic  
acid formed from 4-ethynylbiphenyl by washed microsomes incubated with 
an 1802 atmosphere would contain one 180 atom per molecule ( I  below).
To investigate the possib ility  of d irect addition of water to the tr ip le  
bond and subsequent oxidation to the acid derivative, semicarbazide 
could be incorporated into the incubation system to trap the ketone (or 
aldehyde) intermediates as th e ir semicarbazides (S ch iff's  bases), Scheme 
I I  below.
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NNHCONH,
H
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S chiff's  bases
The S chiff's  bases thus produced would be stable and capable o f iso lation
There is evidence that some acetylenic compounds characteristically  
undergo hydroxylation a- to the tr ip le  bond. Examples are N-(5-pyrrolidino-
3-pentynyl) succinimide (Lindeke, Hallstrbm, Anderson, and Karlen 1977) 
and pargyline, N-benzyl-N-methyl-propynyl-2-amide, (D iehl, Najm, W olff, 
and Ehrhardt 1976).
N-CH2-CH2-C=C-CH2- N
N -  (5 -  py r  ro 1 i d i no -3 - p en ty ny 1) s u cc i n i m i d e
: I '  ,
N-CH0CH-CEC-CH2-N
Ah
N-(5-Pyrrolidino-2-hydroxy-3-pentynyl)succinimide
CH3 I I
:H CH CsCH 2 2
Pargyline
Whether hydroxylation a- to acetylenic bonds w ill prove to be a 
characteristic reaction with some compounds remains to be seen, fo r very 
l i t t l e  work has been performed in this area. Reaction I above was 
microsomal, inducible with phenobarbitone, and inhibited by SKF 525A, 
carbon monoxide, and nicotinamide. Metabolism prio r to phenobarbitone 
induction was minimal. The reaction therefore seems to be mediated 
by an inducible cytochrome P-450 system.
The absence of tr ip le  bond oxidation in the metabolism of several 
drugs may be because they are themselves a- acetylenic alcohols. The 
absence of ethynyl group metabolism in ethynyloestradiol might thus be 
explained:
The metabolism of acetylenic compounds is an area that has received 
l i t t l e  attention and there remains great scope fo r investigations into  
sites and mechanisms of tr ip le  bond oxidation (and/or reduction). The 
marked differences in the biological s ta b ility  of d iffe ren t acetylenic 
compounds in mammalian organisms needs explanation, for in addition to 
exposure from acetylenic material in natural foodstuffs alkynylation  
has become increasingly widespread in drug design (see Chapter One).
The rapid metabolism of the ethynyl group in  4-ethynylbiphenyl has 
shown that the carbon-carbon tr ip le  bond is not as stable in biological 
systems as previously thought.
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1 MASS SPECTROSCOPY SPECTRA
Electron impact mass spectroscopy was used for identifica tion  o f 
metabolites and characterization of standards. Methods have been 
described e a rlie r  (Chapters Two and Three).
During early studies the major metabolite in ra t urine was 
derivatized with diazomethane and BTFSA (see Chapter Three) and its  
mass-spectrum obtained to aid id en tifica tio n . The spectrum produced 
is shown in Figure 1. There were two possible structures that would 
explain this spectrum:
O G s
COOCHg
(CH3) s
I I  (Cfi3) 3Si ch2cooch3
Accurate mass measurements were recorded for the three principal 
peaks:
Error (ppm)
m/e 314.1348 C18H2203S.i requires 314.1338 3.2
m/e 299.1091 C17H190Sf requires 299.1103 4.0
m/e 255.1238 C16H130Si requires 255.1203 12.9
To determine the true structure, both 4'-hydroxy-4-biphenyly!aceti 
acid and 4-phenylmandelic acid were synthesised:
r\-r%- ch2cooh
4 1-Hydroxy-4-biphenylylacetic acid
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CH-COOH
p-Phenylmandelic.acid
Although these two compounds possess the same molecular weight 
(228) th e ir fragmentation patterns are quite d iffe ren t (Figure 2 and 
Figure 3 ) . 4LHydroxy-4 4 )iphenylylacetic acid gives a strong parent 
peak (M? 228) and the principal fragment a t m/^ e 183 represents the
4.
loss of -C00H (M* 45) to produce the tropylium ion, which being very 
stable is the major peak in the spectrum:
COOH
HQHO
4-Hydroxy-4-biphenylylacetic acid Very stable 4 ‘-hydroxy-4-
phenyltropylium ion
(ra/e 228} (m/e 183)
The phenolic -OH group is very stable.
In contrast, 4-phenylmandelic acid gives only a very small 
molecular ion (m^ e 228). In this spectrum the major peak is at m^ e 154, 
corresponding to the biphenyl molecular ion, whilst m^ e 183 is also 
very prominent. A third important fragment appears at m^ e 167, 
corresponding to the phenyltropuliurn ion. These results combined with 
NMR spectra (given la te r) confirmed the structure of the major metabolite 
in ra t and rabbit as 4-hydroxy-4-biphenyly!acetic acid. Trace amounts 
of a metabolite giving identical spectra to that of 4-phenylmandelic 
acid were found in urine o f ra t and rabbit.
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The spectrum of 4-biphenylylacetic acid is shown in Figure 4.
This is a very simple spectrum, a strong molecular ion a t m^ e 212, 
and the principal peak at m/e  167 corresponding to the 4-phenyl- 
tropylium ion. Metabolites producing identical spectra were found 
in urine, plasma, b ile , and faeces o f both species, and in extracts 
of i n  v i t r o  incubates with ra t liv e r  subcellular fractions.
The spectrum of 4-acetyl biphenyl standard is shown in Figure 5. 
Trace amounts of a metabolite giving 'identical'.'spectra were found in 
plasma.
The spectrum of the parent drug, 4-ethynylbiphenyl is  shown in 
Figure 6. The molecular ion, m^ e 178 is very strong and the spectrum 
shows 1i t t l e  fragmentation.
The spectrum of a metabolite formed in small amounts in rat 
caecal incubates is shown in Figure 7. Like the spectrum of 4-ethynyl- 
biphenyl there is only one predominant peak, but a t m/e  181. This is 
lik e ly  to correspond to 4-vinylbiphenyl, although no standard was 
available for comparison.
'v
m/e 181
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I I NUCLEAR MAGNETIC RESONANCE SPECTRA
The proton n.m.r. spectra of 4 ‘ -hydro xy-4-biphenylyl acetic acid 
and 4-phenylmandelic acid.are shown in Figures 8 and 9. The spectrum 
of the major metabolite o f ra t is shown in Figure 10. Comparison of 
these spectra demonstrates clearly the identity  of the metabolite to 
be 4'-hydroxy-4-biphenylylacetic acid. The protons o f the methylene 
bridge o f this compound produce a characteristic peak a t 3.60, signal 
strength equivalent to 25% of that given by the eight aromatic protons 
of the molecule (6 .8 -7 .5 ). The peaks produced by the spin-spin in te r­
actions of the aromatic protons confirm the p<mz-substitution a t both 
the 4 ' - and 4-positions.
I l l  INFRA-RED SPECTRA-
The infra-red spectra o f 4-ethynylbiphenyl, and the standards 
of 4'-hydroxy-4-biphenylylacetic and 4-phenylmandelic acid are 
shown in Figures 12, 13, and 14, respectively.
IV TISSUE DISTRIBUTION RESULTS
Detailed results of these studies are given in Table 1.
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Table 1. Tissue Distribution o f 4 - [1IfC]Ethynylbiphenyl in Rat
Tissue 1H 2H 4H 6H 10H 16H 24H
* *
24H
Adipose 
(Dorsal)
66
(38-88)
97- 167 206 124 67 79 
(69-117)(115-198)(137-312)(101-145)(59-74) (71-93) 80 55
Adipose
(Epidymal)
28
(17-33)
61 102 140 93 51 60 
(36-76) (68t122) (90-300) (75-126) (52-47) (56-65) 66 52
Li ver 46
(42-49)
43 53 56 28 15 16 
(38-48) (46-59) (49-62) (22-32) (11-17) (12-20) 17 17
Kidney 28
(22-33)
26 31 35 39 20 13 
(24-29) (30-32) (32-36) (23-50) (17-22) (12-14) 13 14
Lung ; 26
(23-30)
27 21 25 25 9.0 6.0 
(25-28) (21-23) (23-26) (18-30) ( 7 -10 )(5 .5 -6 .0 ) 5.5 4 .0
Spleen 10.0 8.0 8.0 10.5 9.0 2.0 
(9 .5 -1 0 .5 )(7 .5 -9 .0 )(7 .0 -8 .5 )(9 1 5 -1 1 .5 )(5 .5 -1 1 .5 )(2 .0 -3 .0 ) 0 .5 0 .5
Brain 11.0 11 .0 10.0 7.0 4.0 1 .0 
(8 .5 -1 3 .5 )(1 0 .5 -1 1 .0 )(8 .5 -1 4 )(6 .5 -8 .0 )(3 .5 -4 .5 ) (0 -1 .5 ) 2 .0 1.0
Muscle 7.0 7.0 8.0 8.0 8.5 1.0 1.0 
(5-8.) (6 .5 -7 .0 )(7 .5 -8 .5 )(7 .5 -9 .0 )(5 .0 -1 0 .5 ) (0—2) (0-1 .0) 2.5 2 .0
Testes
(Ovaries)
7.0 9.0 9.0 12.0 10.0 3.0 2.0  
(4 .5 -8 .5 )(7 .5 -1 0 )(8 ,5 -9 .5 )(1 0 .5 T l5 i O )(6 ,5 -12 .0 ):(2 .5 -3 .0 )(l '5 -2 .5 ) 0.5 0 .5
Seminal
Vesicles
2 1 .5 2.0 2.5 2.0 1 .0 -  
(1 .5 -2 .0 )(1 .0 -2 .5 ) (1 .5 -2 .5 )(2 .0 -3 .5 ) (1 .5 -2 .5 )(1 .5 -2 .0 ) 2 .0 11.5
Stomach 2610 1411 429 281 90 119 2.0
(1634-3207)(1427-1341}(367-522)[118-524)(33-133)(36-124) (0-5)
Small
Intestine
*
Large
Intestine
Adrenal
Heart
794 404 340 760 740 238 145
(313-10691(254-497)(1 82-429)(264-1511)(579-853)(210-274)(90-253)
8.0  10.0
72 142
68 74 348 542 549 367 171
(45-8^) (80-701 (251-484)(502-578) (513-570)(316-459)(116-202)
2.0 3.0 2.0 3.0 1 .0 0.5
(1 .5 -3 .0 ) (2 .5 -3 .5 ) (1 .0 -3 .0 )(2 .0 -3 .5 ) (0 -2 .0 ) (0 -1 .0 )
340 345
0 .5  0 .5
16 14 16 18 16 4
(11-20) (14-15) (14-17) (17-19) (13-18) (3-4) (2 .5 -3 .0 )2 ,0  1 "5
I
Tissue distribution o f [IIfC]in the ra t following a single oral dose o f 4 - [ ll+C]
Ethynylbiphenyl (40 mg/kg). Results are expressed as g drug equivalent/g tissue 
at various time intervals a fte r dosing and are the mean of three animals (range 
shown in parentheses).
*  jjg Drug equiv./organ
* *  Figures for two rats dosed daily (40 mg/kg) for four days.
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